Dupilumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 29, 2026

The clinical evidence base for Dupilumab comprises 437 peer-reviewed publications across 15 journals, 60 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Dermatitis, Atopic, Asthma, Eosinophilic Esophagitis, and Nasal Polyps. Most recent publication: Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)., Dermatol Ther (Heidelb), 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, et al. · Lancet · 2016
PubMed: PMID 27130691 · NCT01854047 · Asthma
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Thaçi D, Simpson EL, Beck LA, et al. · Lancet · 2016
PubMed: PMID 26454361 · NCT01859988 · Dermatitis, Atopic
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL, Gadkari A, Worm M, et al. · J Am Acad Dermatol · 2017
PubMed: PMID 27268421 · NCT01859988 · Dermatitis, Atopic
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, et al. · N Engl J Med · 2017
PubMed: PMID 27690741 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.
Simpson EL, Bieber T, Eckert L, et al. · J Am Acad Dermatol · 2016
PubMed: PMID 26777100 · NCT01859988 · Dermatitis, Atopic
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF, Nair P, Brusselle G, et al. · N Engl J Med · 2018
PubMed: PMID 29782224 · NCT05331755 (RELYonDupi) · Asthma
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, et al. · N Engl J Med · 2018
PubMed: PMID 29782217 · NCT02414854 · Asthma
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, et al. · JAMA Dermatol · 2022
PubMed: PMID 34347860 · NCT03738397 (Heads Up) · Dermatitis, Atopic

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

Trial	Indication	Primary endpoint	Arm	Value
NCT01949311	Dermatitis, Atopic	Number of Treatment Emergent Adverse Events (TEAEs) Up to 272 weeks	Dupilumab	14717 Number of Events
NCT01949311	Dermatitis, Atopic	OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug Product Up to 24 Weeks	Dupilumab	0 Events
NCT02134028	Asthma	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From the first IMP injection in LTS12551 to the last IMP injection plus 14 weeks (up to 108 weeks)	Participants From DRI12544: Dupilumab/Dupilumab	369 Participants
			Participants From DRI12544: Dupilumab/Dupilumab	19 Participants
			Participants From DRI12544: Dupilumab/Dupilumab	3 Participants
			Participants From DRI12544: Dupilumab/Dupilumab	42 Participants
			Participants From DRI12544: Placebo/Dupilumab	88 Participants
			Participants From DRI12544: Placebo/Dupilumab	3 Participants
			Participants From DRI12544: Placebo/Dupilumab	0 Participants
			Participants From DRI12544: Placebo/Dupilumab	14 Participants
			Participants From EFC13579: Dupilumab/Dupilumab	31 Participants
			Participants From EFC13579: Dupilumab/Dupilumab	789 Participants
			Participants From EFC13579: Dupilumab/Dupilumab	106 Participants
			Participants From EFC13579: Dupilumab/Dupilumab	1 Participants
			Participants From EFC13579: Placebo/Dupilumab	48 Participants
			Participants From EFC13579: Placebo/Dupilumab	414 Participants
			Participants From EFC13579: Placebo/Dupilumab	12 Participants
			Participants From EFC13579: Placebo/Dupilumab	0 Participants
			Participants From EFC13691: Dupilumab/Dupilumab	0 Participants
			Participants From EFC13691: Dupilumab/Dupilumab	70 Participants
			Participants From EFC13691: Dupilumab/Dupilumab	10 Participants
			Participants From EFC13691: Dupilumab/Dupilumab	5 Participants
			Participants From EFC13691: Placebo/Dupilumab	4 Participants
			Participants From EFC13691: Placebo/Dupilumab	74 Participants
			Participants From EFC13691: Placebo/Dupilumab	12 Participants
			Participants From EFC13691: Placebo/Dupilumab	0 Participants
			Participants From PDY14192: Dupilumab/Dupilumab	0 Participants
			Participants From PDY14192: Dupilumab/Dupilumab	2 Participants
			Participants From PDY14192: Dupilumab/Dupilumab	13 Participants
			Participants From PDY14192: Dupilumab/Dupilumab	4 Participants
			Participants From PDY14192: Placebo/Dupilumab	18 Participants
			Participants From PDY14192: Placebo/Dupilumab	1 Participants
			Participants From PDY14192: Placebo/Dupilumab	0 Participants
			Participants From PDY14192: Placebo/Dupilumab	0 Participants
NCT02260986 CHRONOS	Dermatitis, Atopic	Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 Baseline to Week 16	Dupilumab 300 mg q2w	38.7 percentage of participants
			Dupilumab 300 mg qw	39.2 percentage of participants
			Placebo qw	12.4 percentage of participants
NCT02277743 SOLO 1	Dermatitis, Atopic	Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 Week 16	Dupilumab 300 mg q2w	37.9 percentage of participants
			Dupilumab 300 mg qw	37.2 percentage of participants
			Placebo	10.3 percentage of participants
NCT02277769 SOLO 2	Dermatitis, Atopic	Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 Week 16	Dupilumab 300 mg q2w	36.1 percentage of participants
			Dupilumab 300 mg qw	36.4 percentage of participants
			Placebo	8.5 percentage of participants
NCT02395133 SOLO-CONTINUE	Dermatitis, Atopic	Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769) Baseline (Parent Study), Baseline (Current Study) and Week 36 (Current study)	Dupilumab 300 mg Q2W/QW	0.06 percent change (±1.736 Standard Error)
			Dupilumab 300 mg Q4W	3.84 percent change (±2.283 Standard Error)
			Dupilumab 300 mg Q8W	6.84 percent change (±2.434 Standard Error)
			Placebo QW	21.67 percent change (±3.134 Standard Error)
NCT02395133 SOLO-CONTINUE	Dermatitis, Atopic	Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36 Week 36	Dupilumab 300 mg Q2W/QW	71.6 percentage of participants
			Dupilumab 300 mg Q4W	58.3 percentage of participants
			Dupilumab 300 mg Q8W	54.9 percentage of participants
			Placebo QW	30.4 percentage of participants
NCT02414854	Asthma	Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population Baseline, Week 12	Dupilumab 200 mg q2w	1.78 liter (±0.62 Standard Deviation)
			Dupilumab 200 mg q2w	0.28 liter (±0.45 Standard Deviation)
			Dupilumab 200 mg q2w	2.07 liter (±0.76 Standard Deviation)
			Dupilumab 300 mg q2w	1.78 liter (±0.60 Standard Deviation)
			Dupilumab 300 mg q2w	0.31 liter (±0.43 Standard Deviation)
			Dupilumab 300 mg q2w	2.09 liter (±0.70 Standard Deviation)
			Placebo (for Dupilumab 200 mg) q2w	1.92 liter (±0.70 Standard Deviation)
			Placebo (for Dupilumab 200 mg) q2w	1.76 liter (±0.61 Standard Deviation)
			Placebo (for Dupilumab 200 mg) q2w	0.15 liter (±0.36 Standard Deviation)
			Placebo (for Dupilumab 300 mg) q2w	0.18 liter (±0.39 Standard Deviation)
			Placebo (for Dupilumab 300 mg) q2w	1.93 liter (±0.68 Standard Deviation)
			Placebo (for Dupilumab 300 mg) q2w	1.75 liter (±0.57 Standard Deviation)
NCT02414854	Asthma	Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population Baseline to Week 52	Dupilumab 200 mg q2w	0.456 Exacerbation per participant-year
			Dupilumab 300 mg q2w	0.524 Exacerbation per participant-year
			Placebo (for Dupilumab 200 mg) q2w	0.871 Exacerbation per participant-year
			Placebo (for Dupilumab 300 mg) q2w	0.970 Exacerbation per participant-year
NCT02528214 VENTURE	Asthma	Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control Baseline, Week 24	Dupilumab 300 mg q2w	70.09 Percentage reduction from baseline (±4.90 Standard Error)
NCT02528214 VENTURE	Asthma		Placebo q2w	41.85 Percentage reduction from baseline (±4.57 Standard Error)
NCT02528214 VENTURE	Asthma	Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control Baseline, Week 24	Dupilumab 300 mg q2w	100.0 percentage reduction from baseline
NCT02528214 VENTURE	Asthma		Placebo q2w	50.0 percentage reduction from baseline
NCT02755649	Dermatitis, Atopic	Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16 Baseline, Week 16	Dupilumab 300 mg Q2W + TCS	62.6 Percentage of Participants
			Dupilumab 300 mg QW + TCS	59.1 Percentage of Participants
			Placebo QW + TCS	29.6 Percentage of Participants
NCT02898454 SINUS-52	—	Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score Baseline, Week 24	Dupilumab 300 mg (24 Weeks Pooled Arm)	-1.25 score on a scale (±0.06 Standard Error)
NCT02898454 SINUS-52	—		Placebo	-0.38 score on a scale (±0.07 Standard Error)
NCT02898454 SINUS-52	—	Change From Baseline at Week 24 in Nasal Polyp Score Baseline, Week 24	Dupilumab 300 mg (24 Weeks Pooled Arm)	-1.71 score on a scale (±0.11 Standard Error)
NCT02898454 SINUS-52	—		Placebo	0.10 score on a scale (±0.14 Standard Error)
NCT02912468 SINUS-24	Nasal Polyps	Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score Baseline, Week 24	Dupilumab 300 mg	-1.34 score on a scale (±0.07 Standard Error)
NCT02912468 SINUS-24	Nasal Polyps		Placebo	-0.45 score on a scale (±0.07 Standard Error)
NCT02912468 SINUS-24	Nasal Polyps	Change From Baseline at Week 24 in Nasal Polyp Score Baseline, Week 24	Dupilumab 300 mg	-1.89 score on a scale (±0.14 Standard Error)
NCT02912468 SINUS-24	Nasal Polyps		Placebo	0.17 score on a scale (±0.15 Standard Error)
NCT02948959 VOYAGE	Asthma	Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population Baseline to Week 52	Dupilumab	0.235 exacerbations per participant-years
NCT02948959 VOYAGE	Asthma		Placebo	0.665 exacerbations per participant-years
NCT02948959 VOYAGE	Asthma	Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population Baseline to Week 52	Dupilumab	0.305 exacerbations per participant-years
NCT02948959 VOYAGE	Asthma		Placebo	0.748 exacerbations per participant-years
NCT03054428	Dermatitis, Atopic	Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (≥75% Improvement From Baseline) at Week 16 Baseline and Week 16	Dupilumab 200 mg or 300 mg Q2W	41.5 Percentage of participants
			Dupilumab 300 mg Q4W	38.1 Percentage of participants
			Placebo	8.2 Percentage of participants
NCT03054428	Dermatitis, Atopic	Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16 Baseline and Week 16	Dupilumab 200 mg or 300 mg Q2W	24.4 Percentage of participants
			Dupilumab 300 mg Q4W	17.9 Percentage of participants
			Placebo	2.4 Percentage of participants
NCT03345914	Dermatitis, Atopic	Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16 Week 16	Dupilumab 100 mg or 200 mg Q2W + TCS	29.5 Percentage of Participants
			Dupilumab 300 mg Q4W + TCS	32.8 Percentage of Participants
			Placebo + TCS	11.4 Percentage of Participants
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) of Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	198 DaysMilligrams per Liter (daymg/L) (±125 Standard Deviation)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	622 DaysMilligrams per Liter (daymg/L) (±184 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	123 DaysMilligrams per Liter (daymg/L) (±86.0 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	493 DaysMilligrams per Liter (daymg/L) (±294 Standard Deviation)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Dose Normalized Area Under the Serum Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast/Dose) of Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	66.0 [day*mg/L]/[mg/kg] (±41.6 Standard Deviation)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	104 [day*mg/L]/[mg/kg] (±30.6 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	41.0 [day*mg/L]/[mg/kg] (±28.7 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	82.1 [day*mg/L]/[mg/kg] (±48.9 Standard Deviation)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Dose Normalized Maximum Observed Serum Concentration (Cmax/Dose) of Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	8.39 [mg/L]/[mg/kg] (±2.48 Standard Deviation)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	8.30 [mg/L]/[mg/kg] (±1.89 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	6.70 [mg/L]/[mg/kg] (±2.27 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	7.68 [mg/L]/[mg/kg] (±1.86 Standard Deviation)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Last Quantifiable Serum Concentration (Clast) of Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	6.64 mg/L (±6.16 Standard Deviation)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	6.14 mg/L (±4.69 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	5.64 mg/L (±4.52 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	15.1 mg/L (±9.48 Standard Deviation)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	25.2 Milligrams per Liter (mg/L) (±7.44 Standard Deviation)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	49.8 Milligrams per Liter (mg/L) (±11.3 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	20.1 Milligrams per Liter (mg/L) (±6.81 Standard Deviation)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	46.1 Milligrams per Liter (mg/L) (±11.1 Standard Deviation)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) Baseline up to Week 4	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	3 Participants
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	2 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	7 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	7 Participants
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Number of Participants With TEAEs by Severity According to Qualitative Toxicity Scale Baseline up to Week 4	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	2 Participants
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	1 Participants
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	0 Participants
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	0 Participants
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	0 Participants
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	2 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	4 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	2 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	1 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	0 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	2 Participants
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	5 Participants
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Time of the Last Quantifiable Serum Concentration (Tlast) of Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	14.8 Days (±6.79 Full Range)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	26.5 Days (±15.0 Full Range)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	8.56 Days (±6.88 Full Range)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	16.0 Days (±6.95 Full Range)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part A: Time to Reach the Maximum Serum Concentration (Tmax) of Dupilumab Post-dose on Days 1, 3, 8, 18, and 29	Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 3 mg/kg	1.92 Days (±1.72 Full Range)
			Part A: Cohort 1 (≥2 to <6 Years Old): Dupilumab 6 mg/kg	1.97 Days (±1.87 Full Range)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 3 mg/kg	1.95 Days (±1.75 Full Range)
			Part A: Cohort 2 (≥6 Months to <2 Years): Dupilumab 6 mg/kg	2.10 Days (±1.80 Full Range)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part B: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) (≥75% Improvement From Baseline) at Week 16 Week 16	Part B: Dupilumab 200 mg or 300 mg Q4W + TCS	53.0 Percentage of Participants (±41.74 95% Confidence Interval)
NCT03346434 Liberty AD	Dermatitis, Atopic		Part B: Placebo + TCS	10.7 Percentage of Participants (±3.65 95% Confidence Interval)
NCT03346434 Liberty AD	Dermatitis, Atopic	Part B: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16 Week 16	Part B: Dupilumab 200 mg or 300 mg Q4W + TCS	27.7 Percentage of Participants (±18.45 95% Confidence Interval)
NCT03346434 Liberty AD	Dermatitis, Atopic		Part B: Placebo + TCS	3.9 Percentage of Participants (±-0.42 95% Confidence Interval)
NCT03560466	Asthma	Japan Sub-study: Change From Baseline to Week 12 in Pre-Bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Baseline (Day 1) to Week 12	Japan Sub-study: Dupilumab	7.08 percent predicted FEV1 (±6.78 Standard Deviation)
NCT03560466	Asthma	Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs) From first dose of study treatment (Day 1) up to 112 days post last dose of study treatment, approximately 64 weeks	Main Study: Dupilumab-Dupilumab	147 Participants
NCT03560466	Asthma		Main Study: Placebo-Dupilumab	85 Participants
NCT03620747	Asthma	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)	Dupilumab	54.5 percentage of participants
NCT03620747	Asthma	Treatment-emergent Adverse Event Rate (Event Per 100 Participant-years) From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)	Dupilumab	171.4 events per 100 participant-years
NCT03633617	Eosinophilic Esophagitis	Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Total Score at Week 24 Baseline and week 24	Part A: Dupilumab 300 mg SC QW	-21.92 Score on a Scale
			Part A: Placebo	-9.60 Score on a Scale
			Part B: Dupilumab 300 mg SC Q2W	-14.37 Score on a Scale
			Part B: Dupilumab 300 mg SC QW	-23.78 Score on a Scale
			Part B: Placebo	-13.86 Score on a Scale
NCT03633617	Eosinophilic Esophagitis	Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of ≤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24 At week 24	Part A: Dupilumab 300 mg SC QW	59.5 Percentage of Participants
			Part A: Placebo	5.1 Percentage of Participants
			Part B: Dupilumab 300 mg SC Q2W	60.5 Percentage of Participants
			Part B: Dupilumab 300 mg SC QW	58.8 Percentage of Participants
			Part B: Placebo	6.3 Percentage of Participants
NCT03720470 JADE Compare	Dermatitis, Atopic	Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75 Percent (%) Improvement From Baseline at Week 12 Baseline, Week 12	Dupilumab 300 mg + Oral Placebo up to Week 16	58.1 Percentage of participants
			PF-04965842 100 mg + Placebo Injection up to Week 16	58.7 Percentage of participants
			PF-04965842 200 mg + Placebo Injection up to Week 16	70.3 Percentage of participants
			Placebo up to Week 16	27.1 Percentage of participants
NCT03720470 JADE Compare	Dermatitis, Atopic	Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Week 12 Baseline (the last measurement prior to first dosing on Day 1), Week 12	Dupilumab 300 mg + Oral Placebo up to Week 16	36.5 Percentage of participants
			PF-04965842 100 mg + Placebo Injection up to Week 16	36.6 Percentage of participants
			PF-04965842 200 mg + Placebo Injection up to Week 16	48.4 Percentage of participants
			Placebo up to Week 16	14.0 Percentage of participants
NCT03738397 Heads Up	Dermatitis, Atopic	Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16 Baseline and Week 16	Dupilumab 300 mg EOW	62.6 percentage of participants
NCT03738397 Heads Up	Dermatitis, Atopic		Upadacitinib 30 mg QD	72.4 percentage of participants
NCT03912259	Dermatitis, Atopic	Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 Baseline, Week 16	Dupilumab 300 mg Q2W	22 Participants
NCT03912259	Dermatitis, Atopic		Placebo Q2W	4 Participants
NCT03930732 BOREAS	Pulmonary Disease, Chronic Obstructive	Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period Baseline (Day 1) to Week 52	Dupilumab 300 mg q2w	0.776 exacerbation per participant-year
NCT03930732 BOREAS	Pulmonary Disease, Chronic Obstructive		Placebo	1.01 exacerbation per participant-year
NCT04180488	Chronic Urticaria	Change From Baseline in Weekly Itch Severity Score at Week 24 Baseline (Day 1) and Week 24	Study A: Dupilumab	-10.24 score on a scale (±0.91 Standard Error)
			Study A: Placebo	-6.01 score on a scale (±0.94 Standard Error)
			Study B: Dupilumab	-7.68 score on a scale (±1.10 Standard Error)
			Study B: Placebo	-4.81 score on a scale (±1.08 Standard Error)
			Study C: Dupilumab	-8.64 score on a scale (±1.41 Standard Error)
			Study C: Placebo	-6.10 score on a scale (±1.40 Standard Error)
NCT04183335	Neurodermatitis	Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to Week 24 Baseline, Week 24	Dupilumab 300 mg Q2W	60.0 percentage of participants
NCT04183335	Neurodermatitis		Placebo	18.4 percentage of participants
NCT04202679	Neurodermatitis	Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week 12 Baseline, Week 12	Dupilumab 300 mg Q2W	37.2 percentage of participants
NCT04202679	Neurodermatitis		Placebo	22.0 percentage of participants
NCT04206553 LIBERTY-BP	Pemphigoid, Bullous	Percent of Participants Achieving Sustained Remission at Week 36 At Week 36	Dupilumab Q2W	18.2 Estimated Percentage of Participants
NCT04206553 LIBERTY-BP	Pemphigoid, Bullous		Placebo	4.0 Estimated Percentage of Participants
NCT04345367	Dermatitis, Atopic	Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4 Week 4	Abrocitinib 200 mg QD	28.5 Percentage of participants
NCT04345367	Dermatitis, Atopic		Dupilumab 300 mg Q2W	14.6 Percentage of participants
NCT04345367	Dermatitis, Atopic	Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 Week 2	Abrocitinib 200 mg QD	48.2 Percentage of participants
NCT04345367	Dermatitis, Atopic		Dupilumab 300 mg Q2W	25.5 Percentage of participants
NCT04394351 EoE KIDS	Eosinophilic Esophagitis	Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16 At Week 16	Part A: Dupilumab High Dose	67.6 percentage of participants
			Part A: Dupilumab Low Dose	58.1 percentage of participants
			Part A: Pooled Placebo	2.9 percentage of participants
NCT04417894	—	Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 At week 16	Dupilumab Q2W	40.3 Percentage of participants
NCT04417894	—		Matching Placebo	16.7 Percentage of participants
NCT04456673 NOTUS	Pulmonary Disease, Chronic Obstructive	Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period Baseline (Day 1) to Week 52	Dupilumab 300 mg q2w	0.859 Exacerbation per participant-year
NCT04456673 NOTUS	Pulmonary Disease, Chronic Obstructive		Placebo	1.295 Exacerbation per participant-year
NCT04678856 Liberty CRSsNP	Sinusitis	Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group Baseline (Day 1) and Week 24	Dupilumab 300 mg q2w	-6.63 Score on a scale (±3.91 Standard Deviation)
NCT04681729	Cold Urticaria	Percentage of Participants With Negative Ice Cube Provocation Test at Week 24 Week 24	Dupilumab	40.5 percentage of participants
NCT04681729	Cold Urticaria		Placebo	37.5 percentage of participants
NCT04684524	Allergic Fungal Sinusitis	Change From Baseline to Week 52 in Opacification of Sinuses Assessed by CT Scan Using the LMK Score Baseline (Day 1) and Week 52	Dupilumab	-9.17 score on a scale (±0.74 Standard Error)
NCT04684524	Allergic Fungal Sinusitis		Placebo	-1.81 score on a scale (±0.81 Standard Error)
NCT05526521	Chronic Urticaria	Serum Concentration of Dupilumab at Weeks 12 and 24 Weeks 12 and 24	Dupilumab 200 mg Q2W, 400 mg Loading Dose	78500 nanogram/milliliter (±31600 Standard Deviation)
			Dupilumab 200 mg Q2W, 400 mg Loading Dose	91600 nanogram/milliliter (±23000 Standard Deviation)
			Dupilumab 200 mg Q4W	67700 nanogram/milliliter
			Dupilumab 200 mg Q4W	116000 nanogram/milliliter
			Dupilumab 300 mg Q4W	141000 nanogram/milliliter (±30100 Standard Deviation)
			Dupilumab 300 mg Q4W	105000 nanogram/milliliter
			Dupilumab 300 mg Q4W, 600 mg Loading Dose	45800 nanogram/milliliter (±12400 Standard Deviation)
			Dupilumab 300 mg Q4W, 600 mg Loading Dose	51100 nanogram/milliliter (±20100 Standard Deviation)
NCT05545072 ADAPT	Allergic Fungal Sinusitis	Incidence of Oral/Topical Corticosteroid Utilization Per Participant Baseline and End of Treatment at Week 52	Dupilumab	0 Participants
			Dupilumab	0 Participants
			Dupilumab	3 Participants
			Placebo	2 Participants
			Placebo	0 Participants
NCT05601882 Level Up	Dermatitis, Atopic	Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16 Baseline and Week 16	Dupilumab (Period 1)	8.9 percentage of participants
NCT05601882 Level Up	Dermatitis, Atopic		Upadacitinib (Period 1)	19.9 percentage of participants
NCT05878093	—	Change From Baseline in Nasal Polyps Score at Week 24 Baseline (Day 1) and Week 24	Dupilumab 300 mg q2w	-2.34 score on a scale (±0.30 Standard Error)
NCT05878093	—		Placebo	-0.50 score on a scale (±0.30 Standard Error)

Publications by year

1982–2026: 437 publications.

1982

1984

1987

1994

1995

1996

1997

1999

2000

2001

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Publications by indication

Dermatitis, Atopic (115)

Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE.
Am J Clin Dermatol · 2026 · PMID 42084697 · NCT03720470
Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb) · 2026 · PMID 41102518 · NCT02260986
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.
Adv Ther · 2026 · PMID 41563707 · NCT01949311
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.
Dermatol Ther (Heidelb) · 2026 · PMID 42162528 · NCT04345367
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis.
Am J Clin Dermatol · 2026 · PMID 41903092 · NCT02612454

Asthma (95)

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
Clin Exp Allergy · 2026 · PMID 41309110 · NCT04442256
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).
Ann Allergy Asthma Immunol · 2026 · PMID 41967704 · NCT07309614
Improved asthma outcomes for dupilumab plus medium-dose inhaled corticosteroids versus placebo plus high-dose inhaled corticosteroids.
Ann Allergy Asthma Immunol · 2026 · PMID 42178021 · NCT02414854
Dual Remission in Patients with Moderate-to-Severe Asthma and CRSwNP Treated with Dupilumab: A 24-Month Real-World Study.
J Clin Med · 2026 · PMID 41977087 · NCT07574294
Two-Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage.
Allergy · 2026 · PMID 40884177 · NCT07574294

Eosinophilic Esophagitis (44)

Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis.
Clin Gastroenterol Hepatol · 2026 · PMID 41038415 · NCT05247866
Dupilumab improves symptoms and quality of life in patients with eosinophilic esophagitis: a plain language summary.
Immunotherapy · 2026 · PMID 42093592 · NCT03633617
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Gastroenterol Hepatol · 2026 · PMID 37660704 · NCT03633617
Dupilumab normalizes the eosinophilic esophagitis disease transcriptome.
J Allergy Clin Immunol · 2026 · PMID 42031097 · NCT02379052
Baseline characteristics, treatment patterns, and long-term outcomes in patients with eosinophilic esophagitis initiating dupilumab in routine clinical practice: study protocol of a phase IV, prospective, observational, multicenter registry (EDESIA).
Ther Adv Gastroenterol · 2026 · PMID 42100495 · NCT06693531

Nasal Polyps (20)

Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia.
Curr Med Res Opin · 2025 · PMID 39618256 · NCT02912468
Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
BMJ Open · 2024 · PMID 38749694 · NCT05228041
Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
Otolaryngol Head Neck Surg · 2024 · PMID 38156522 · NCT02912468
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.
Clin Exp Allergy · 2022 · PMID 35775319 · NCT02912468
Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps.
Laryngoscope · 2022 · PMID 34437720 · NCT02912468

Pulmonary Eosinophilia (11)

Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies.
Arch Bronconeumol · 2022 · PMID 34167859 · NCT05787678
Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).
Arch Bronconeumol · 2014 · PMID 23726118 · NCT05787678
British guideline on the management of asthma.
Thorax · 2014 · PMID 25323740 · NCT05787678
Flow cytometry analysis of leukocytes in induced sputum from asthmatic patients.
Immunobiology · 2013 · PMID 22204819 · NCT05787678
Validation of the Spanish version of the Asthma Control Test (ACT).
J Asthma · 2008 · PMID 18097865 · NCT05787678

Colorectal Neoplasms (8)

How a hobby farm taught me to set priorities in academia.
Nature · 2024 · PMID 36198820 · NCT07277322
Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
J Clin Oncol · 2022 · PMID 34985936 · NCT07277322
Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
JAMA Netw Open · 2022 · PMID 35258578 · NCT07277322
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Nat Rev Clin Oncol · 2019 · PMID 31092901 · NCT07277322
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Nat Med · 2019 · PMID 30804515 · NCT07277322

Publications by journal

J Allergy Clin Immunol42 papers
Dermatol Ther (Heidelb)34 papers
J Allergy Clin Immunol Pract30 papers
Allergy23 papers
Am J Clin Dermatol19 papers
N Engl J Med14 papers
Ann Allergy Asthma Immunol14 papers
Adv Ther12 papers
Eur Respir J10 papers
Br J Dermatol9 papers

Trial-results highlights

For atopic dermatitis, studies evaluated the percentage of participants achieving an Investigator's Global Assessment (IGA) score of "0" or "1" with a reduction of at least 2 points from baseline at Week 16. In the NCT02260986 (CHRONOS) trial, this was achieved by 38.7% of participants in the Dupilumab 300 mg q2w arm and 39.2% in the Dupilumab 300 mg qw arm, compared to 12.4% in the Placebo qw arm. In the NCT02277743 (SOLO 1) study, 37.9% of participants in the Dupilumab 300 mg q2w arm and 37.2% in the Dupilumab 300 mg qw arm met this endpoint, versus 10.3% in the Placebo arm. Similarly, in NCT02277769 (SOLO 2), 36.1% of participants in the Dupilumab 300 mg q2w arm and 36.4% in the Dupilumab 300 mg qw arm achieved this, compared to 8.5% in the Placebo arm.

Further atopic dermatitis data from NCT02395133 (SOLO-CONTINUE) showed the percentage of participants maintaining Eczema Area and Severity Index (EASI) >= 75% at Week 36. This was achieved by 71.6% of participants in the Dupilumab 300 mg Q2W/QW arm, 58.3% in the Dupilumab 300 mg Q4W arm, 54.9% in the Dupilumab 300 mg Q8W arm, and 30.4% in the Placebo QW arm. The least squares mean percent change in EASI from parent study baseline to Week 36 was 0.06% for Dupilumab 300 mg Q2W/QW, 3.84% for Dupilumab 300 mg Q4W, 6.84% for Dupilumab 300 mg Q8W, and 21.67% for Placebo QW. Regarding safety, the NCT01949311 study reported 14717 treatment-emergent adverse events (TEAEs) in the Dupilumab arm over up to 272 weeks. An optional sub-study of NCT01949311 reported 0 adverse events of special interest (AESIs) in the Dupilumab arm over up to 24 weeks.

For asthma, the NCT02134028 study reported the number of participants with TEAEs over up to 108 weeks.

Participants from DRI12544 in the Dupilumab/Dupilumab arm: 369 participants, 19 participants, 3 participants, and 42 participants.
Participants from DRI12544 in the Placebo/Dupilumab arm: 88 participants and 3 participants.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Dupilumab publications (437)

2026 (32 papers)

Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM).
Yosipovitch G, Mosnaim G, Ortmann CE, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41854973 · NCT06868212 (RECLAIM) · Chronic Urticaria
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
Yosipovitch G, Kim BS, Koo JY, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41272364 · NCT04202679 · Neurodermatitis
Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE.
Yosipovitch G, Gooderham MJ, Elmariah SB, et al. · Am J Clin Dermatol · 2026 · Derived
PubMed: PMID 42084697 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis.
Wolfset N, Muir AB, Benitez AJ, et al. · Clin Gastroenterol Hepatol · 2026 · Derived
PubMed: PMID 41038415 · NCT05247866 · Eosinophilic Esophagitis
Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.
Wiseman M, Benvenuto M, Strømkjær L, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41102518 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Dupilumab improves symptoms and quality of life in patients with eosinophilic esophagitis: a plain language summary.
Strobel MJ, Spergel JM, Chehade M, et al. · Immunotherapy · 2026 · Derived
PubMed: PMID 42093592 · NCT03633617 · Eosinophilic Esophagitis
Dupilumab Improves Prurigo Activity and Severity in Patients with Prurigo Nodularis: A Post Hoc Analysis of Pooled Results from the PRIME and PRIME2 Trials.
Stander S, Zeidler C, Msihid J, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41922877 · NCT04202679 · Neurodermatitis
Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.
Ständer S, Yosipovitch G, Kwatra SG, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 42120670 · NCT04183335 · Neurodermatitis
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, Bissonnette R, Deleuran M, et al. · Adv Ther · 2026 · Derived
PubMed: PMID 41563707 · NCT01949311 · Dermatitis, Atopic
Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.
Silverberg JI, Simpson EL, Farooqui SA, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 42162528 · NCT04345367 · Dermatitis, Atopic
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Rothenberg ME, Dellon ES, Collins MH, et al. · Lancet Gastroenterol Hepatol · 2026 · Derived
PubMed: PMID 37660704 · NCT03633617 · Eosinophilic Esophagitis
Win Ratio Analysis to Clarify Clinical Benefits: A Post Hoc Analysis of Phase 3 BOREAS and NOTUS.
Ramakrishnan S, Petousi N, Bon J, et al. · Chest · 2026 · Derived
PubMed: PMID 41794122 · NCT03930732 (BOREAS) · Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of Treatment with Dupilumab for up to 2 Years in Infants and Young Children with Atopic Dermatitis.
Paller AS, Simpson EL, Siegfried EC, et al. · Am J Clin Dermatol · 2026 · Derived
PubMed: PMID 41903092 · NCT02612454 · Dermatitis, Atopic
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Paller AS, Pinter A, Wine Lee L, et al. · Paediatr Drugs · 2026 · Derived
PubMed: PMID 41926052 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Dupilumab normalizes the eosinophilic esophagitis disease transcriptome.
Lim WK, Wipperman MF, Rothenberg ME, et al. · J Allergy Clin Immunol · 2026 · Derived
PubMed: PMID 42031097 · NCT02379052 · Eosinophilic Esophagitis
Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.
Kim BS, Gonçalo M, Ugajin T, et al. · Am J Clin Dermatol · 2026 · Derived
PubMed: PMID 41219577 · NCT04202679 · Neurodermatitis
The Impact of Dupilumab on Psychological Wellbeing in Moderate-to-Severe Atopic Dermatitis Patients: A Phase IV Clinical Trial.
Johnson CE, Elhage KG, Spencer RK, et al. · J Clin Aesthet Dermatol · 2026 · Derived
PubMed: PMID 42027418 · NCT03667014 · Dermatitis, Atopic
Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naïve Patients with Chronic Spontaneous Urticaria.
Giménez-Arnau AM, Casale TB, Yosipovitch G, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41326897 · NCT04180488 · Chronic Urticaria
Dupilumab step-down strategy to maintain remission in adult and adolescent patients with atopic dermatitis: study protocol for a non-inferiority randomized trial (MADULO).
Foureau A, Faurel-Paul E, Hardouin JB, et al. · Trials · 2026 · Derived
PubMed: PMID 41350756 · NCT05642208 (MADULO) · Dermatitis, Atopic
Identifying the Most Relevant Eczema Area and Severity Index Thresholds from the Patient Perspective in Atopic Dermatitis Treatment.
Eichenfield LF, Lio PA, Irvine AD, et al. · Am J Clin Dermatol · 2026 · Derived
PubMed: PMID 41996013 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
Eckl-Dorna J, Morgenstern C, Poglitsch K, et al. · Clin Exp Allergy · 2026 · Derived
PubMed: PMID 41309110 · NCT04442256 · Asthma
Baseline characteristics, treatment patterns, and long-term outcomes in patients with eosinophilic esophagitis initiating dupilumab in routine clinical practice: study protocol of a phase IV, prospective, observational, multicenter registry (EDESIA).
Dellon ES, Chehade M, McGowan EC, et al. · Ther Adv Gastroenterol · 2026 · Derived
PubMed: PMID 42100495 · NCT06693531 (EDESIA) · Eosinophilic Esophagitis
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).
Couillard S, Petousi N, Ramakrishnan S, et al. · Ann Allergy Asthma Immunol · 2026 · Derived
PubMed: PMID 41967704 · NCT07309614 (HOTHOT) · Asthma
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis.
Cork MJ, Ong PY, Danby SG, et al. · Ann Allergy Asthma Immunol · 2026 · Derived
PubMed: PMID 41611123 · NCT04718870 (PELISTAD) · Dermatitis, Atopic
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.
Cohen D, Bewley A, Wollenberg A, et al. · Dermatol Ther (Heidelb) · 2026 · Derived
PubMed: PMID 41240207 · NCT04417894
Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.
Casale TB, Saini SS, Ben-Shoshan M, et al. · JAMA Dermatol · 2026 · Derived
PubMed: PMID 41706458 · NCT04180488 · Chronic Urticaria
Improved asthma outcomes for dupilumab plus medium-dose inhaled corticosteroids versus placebo plus high-dose inhaled corticosteroids.
Busse WW, Castro M, Lugogo NL, et al. · Ann Allergy Asthma Immunol · 2026 · Derived
PubMed: PMID 42178021 · NCT02414854 · Asthma
Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).
Bunick CG, Magnolo N, Moore A, et al. · Am J Clin Dermatol · 2026 · Derived
PubMed: PMID 41533220 · NCT05601882 (Level Up) · Dermatitis, Atopic
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.
Beck LA, Simpson EL, Thaçi D, et al. · Adv Ther · 2026 · Derived
PubMed: PMID 41999446 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
Bachert C, Laidlaw TM, Cho SH, et al. · Ann Otol Rhinol Laryngol · 2026 · Derived
PubMed: PMID 37322842 · NCT02898454 (SINUS-52)
Dual Remission in Patients with Moderate-to-Severe Asthma and CRSwNP Treated with Dupilumab: A 24-Month Real-World Study.
Menzella F, Berti A, Cestaro W, et al. · J Clin Med · 2026 · Background
PubMed: PMID 41977087 · NCT07574294 (DREAM-NP) · Asthma
Two-Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage.
De Corso E, Montuori C, Pipolo C, et al. · Allergy · 2026 · Background
PubMed: PMID 40884177 · NCT07574294 (DREAM-NP) · Asthma

2025 (26 papers)

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.
Zhang Q, Zhong N, Dhooria S, et al. · Clin Exp Allergy · 2025 · Derived
PubMed: PMID 39988927 · NCT03782532 · Asthma
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.
Vogelmeier CF, Rabe KF, Bhatt SP, et al. · Respir Med · 2025 · Derived
PubMed: PMID 40024335 · NCT03930732 (BOREAS) · Pulmonary Disease, Chronic Obstructive
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials.
Ständer S, Yosipovitch G, Simpson EL, et al. · Adv Ther · 2025 · Derived
PubMed: PMID 39969783 · NCT02395133 (SOLO-CONTINUE) · Dermatitis, Atopic
Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.
Ständer S, Yosipovitch G, Kim BS, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 40971025 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, Silverberg JI, Prajapati VH, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 40457140 · NCT03738397 (Heads Up) · Dermatitis, Atopic
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?
Simpson EL, Silverberg JI, Geng B, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 40987931 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.
Silverberg JI, Simpson EL, Pink AE, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 39903335 · NCT04345367 · Dermatitis, Atopic
Dupilumab Efficacy in Children with Atopic Dermatitis with Different Phenotypes and Endotypes: A Case Series.
Rossi AB, Mello AM, Zahn J, et al. · Adv Ther · 2025 · Derived
PubMed: PMID 40338484 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions.
Pavord ID, Wechsler ME, Busse WW, et al. · J Allergy Clin Immunol Glob · 2025 · Derived
PubMed: PMID 40458676 · NCT02414854 · Asthma
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults.
Langley RG, Gherardi G, Coleman A, et al. · Am J Clin Dermatol · 2025 · Derived
PubMed: PMID 40993471 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia.
Lane AP, Mullol J, Hopkins C, et al. · Curr Med Res Opin · 2025 · Derived
PubMed: PMID 39618256 · NCT02912468 (SINUS-24) · Nasal Polyps
Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGE.
Jackson DJ, Hamelmann E, Roberts G, et al. · J Allergy Clin Immunol Pract · 2025 · Derived
PubMed: PMID 39613097 · NCT02948959 (VOYAGE) · Asthma
Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyps.
Fujieda S, Takabayashi T, Ohta N, et al. · Laryngoscope · 2025 · Derived
PubMed: PMID 40884290 · NCT05049122
Study design of the phase IV, randomized, placebo-controlled REMOdeling with Dupilumab in Eosinophilic esophagitis Long-term (REMODEL) trial.
Dellon ES, Savarino EV, Zaghloul S, et al. · Ther Adv Gastroenterol · 2025 · Derived
PubMed: PMID 41084592 · NCT06101095 · Eosinophilic Esophagitis
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, et al. · Lancet Respir Med · 2025 · Derived
PubMed: PMID 41033334 · NCT04998604 (EVEREST) · Asthma
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.
Christenson SA, Hanania NA, Bhatt SP, et al. · Lancet Respir Med · 2025 · Derived
PubMed: PMID 40651490 · NCT03930732 (BOREAS) · Pulmonary Disease, Chronic Obstructive
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
Chinthrajah RS, Sindher SB, Nadeau KC, et al. · Allergy · 2025 · Derived
PubMed: PMID 39673367 · NCT03793608 · Peanut Hypersensitivity
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.
Castro M, Papi A, Porsbjerg C, et al. · Lancet Respir Med · 2025 · Derived
PubMed: PMID 39947221 · NCT04400318 (VESTIGE) · Asthma
One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
Calzavara-Pinton P, Chu CY, Lapeere H, et al. · Adv Ther · 2025 · Derived
PubMed: PMID 39621227 · NCT03992417 (GLOBOSTAD) · Dermatitis, Atopic
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial.
Bredenoord AJ, Dellon ES, Schlag C, et al. · Expert Rev Gastroenterol Hepatol · 2025 · Derived
PubMed: PMID 39909733 · NCT03633617 · Eosinophilic Esophagitis
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Bhatt SP, Rabe KF, Hanania NA, et al. · Respir Med · 2025 · Derived
PubMed: PMID 39481660 · NCT03930732 (BOREAS) · Pulmonary Disease, Chronic Obstructive
Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.
Bhatt SP, Rabe KF, Hanania NA, et al. · Chest · 2025 · Derived
PubMed: PMID 39894389 · NCT04456673 (NOTUS) · Pulmonary Disease, Chronic Obstructive
Complete/Near-Complete Itch Response Observed in Patients with Moderate-to-Severe Atopic Dermatitis Initiating Dupilumab: 3-Year, Real-World, Interim Data from the PROSE Registry.
Bhatia N, Lynde CW, Fonacier L, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
PubMed: PMID 40234297 · NCT03428646 (PROSE) · Dermatitis, Atopic
Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab.
Bachert C, Khan AH, Hopkins C, et al. · Ann Allergy Asthma Immunol · 2025 · Derived
PubMed: PMID 39343385 · NCT02898454 (SINUS-52)
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.
Asbell P, Akpek E, Chamberlain W, et al. · Adv Ther · 2025 · Derived
PubMed: PMID 40388089 · NCT04287608 · Dermatitis, Atopic
Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography.
Byers RA, Maiti R, Danby SG, et al. · Biomed Opt Express · 2025 · Background
PubMed: PMID 29675335 · NCT05265234 · Dermatitis, Atopic

2024 (40 papers)

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial.
Sasson J, Donlan AN, Ma JZ, et al. · Open Forum Infect Dis · 2024 · Trial result
PubMed: PMID 35959207 · NCT04920916 (SafeDrop) · COVID-19
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM, Hegde S, Park MD, et al. · Nature · 2024 · Trial result
PubMed: PMID 38057662 · NCT06743581 (Dupi-Cemi) · Carcinoma, Non-Small-Cell Lung
Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial.
Hendrick J, Ma JZ, Haughey HM, et al. · medRxiv · 2024 · Trial result
PubMed: PMID 37693596 · NCT04920916 (SafeDrop) · COVID-19
Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
Favier V, Daveau C, Carsuzaa F, et al. · BMJ Open · 2024 · Trial result
PubMed: PMID 38749694 · NCT05228041 (BIOPOSE) · Nasal Polyps
Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China.
Yang N, Ye Y, Shao J, et al. · Dermatitis · 2024 · Derived
PubMed: PMID 36800177 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.
Wipperman MF, Gayvert KM, Atanasio A, et al. · Allergy · 2024 · Derived
PubMed: PMID 38279910 · NCT03558997 · Rhinitis, Allergic
Dupilumab Improves Health-Related Quality of Life and a Range of Symptoms in Patients With Eosinophilic Esophagitis.
Spergel JM, Chehade M, Dellon ES, et al. · Am J Gastroenterol · 2024 · Derived
PubMed: PMID 38940435 · NCT03633617 · Eosinophilic Esophagitis
Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry.
Simpson EL, Lockshin B, Lee LW, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 38175364 · NCT03428646 (PROSE) · Dermatitis, Atopic
Definition of Clinically Meaningful Within-Patient Changes in POEM and CDLQI in Children 6 to 11 Years of Age with Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Bansal A, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 34046851 · NCT03345914 · Dermatitis, Atopic
Abrocitinib may improve itch and quality of life in patients with itch-dominant atopic dermatitis.
Silverberg JI, Thyssen JP, Lazariciu I, et al. · Skin Health Dis · 2024 · Derived
PubMed: PMID 39104653 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series.
Sia T, Bacchus L, Tanaka R, et al. · Clin Transl Gastroenterol · 2024 · Derived
PubMed: PMID 37753954 · NCT05831176 (ENGAGE) · Eosinophilic Esophagitis
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial.
Sasson J, Donlan AN, Ma JZ, et al. · medRxiv · 2024 · Derived
PubMed: PMID 35411349 · NCT04920916 (SafeDrop) · COVID-19
Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial.
Rhee CK, Park JW, Park HW, et al. · Allergy Asthma Immunol Res · 2024 · Derived
PubMed: PMID 39155737 · NCT02134028 · Asthma
Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma.
Peters AT, Sagara H, Corren J, et al. · Ann Allergy Asthma Immunol · 2024 · Derived
PubMed: PMID 38013139 · NCT02414854 · Asthma
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma.
Pavord ID, Casale TB, Corren J, et al. · J Allergy Clin Immunol Pract · 2024 · Derived
PubMed: PMID 38555079 · NCT02414854 · Asthma
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
Paller AS, Siegfried EC, Simpson EL, et al. · Am J Clin Dermatol · 2024 · Derived
PubMed: PMID 38743155 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paller AS, Siegfried EC, Cork MJ, et al. · Paediatr Drugs · 2024 · Derived
PubMed: PMID 38267692 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Paller AS, Pinter A, Wine Lee L, et al. · Adv Ther · 2024 · Derived
PubMed: PMID 38194047 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD.
Paller AS, Gonzalez ME, Barnum S, et al. · Arch Dermatol Res · 2024 · Derived
PubMed: PMID 39080094 · NCT05203380 (NEURADAD)
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Murrell DF, Joly P, Werth VP, et al. · Adv Ther · 2024 · Derived
PubMed: PMID 38443648 · NCT04206553 (LIBERTY-BP) · Pemphigoid, Bullous
Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels.
Maurer M, Casale TB, Saini SS, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 39066978 · NCT04180488 · Chronic Urticaria
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study.
Maspero JF, Peters AT, Chapman KR, et al. · J Allergy Clin Immunol Pract · 2024 · Derived
PubMed: PMID 38163585 · NCT02134028 · Asthma
Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
Kwatra SG, Yosipovitch G, Kim B, et al. · JAMA Dermatol · 2024 · Derived
PubMed: PMID 38865146 · NCT04183335 · Neurodermatitis
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Kamal MA, Kosloski MP, Lai CH, et al. · Front Immunol · 2024 · Derived
PubMed: PMID 39588375 · NCT03054428 · Dermatitis, Atopic
Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
Hopkins C, Mullol J, Khan AH, et al. · Otolaryngol Head Neck Surg · 2024 · Derived
PubMed: PMID 38156522 · NCT02912468 (SINUS-24) · Nasal Polyps
Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study.
Guilbert TW, Murphy KR, Hamelmann E, et al. · J Asthma Allergy · 2024 · Derived
PubMed: PMID 38347908 · NCT02948959 (VOYAGE) · Asthma
New evidence in food allergies treatment.
Ghelli C, Costanzo G, Canonica GW, et al. · Curr Opin Allergy Clin Immunol · 2024 · Derived
PubMed: PMID 38814736 · NCT04148352 · Food Hypersensitivity
Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS-52 trial.
Fokkens WJ, Bachert C, Hopkins C, et al. · Clin Transl Immunology · 2024 · Derived
PubMed: PMID 38854740 · NCT02898454 (SINUS-52)
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
Chehade M, Dellon ES, Spergel JM, et al. · N Engl J Med · 2024 · Derived
PubMed: PMID 38924731 · NCT04394351 (EoE KIDS) · Eosinophilic Esophagitis
Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
Bredenoord AJ, Dellon ES, Hirano I, et al. · Gut · 2024 · Derived
PubMed: PMID 38050037 · NCT03633617 · Eosinophilic Esophagitis
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.
Boguniewicz M, Sher LD, Paller AS, et al. · Adv Ther · 2024 · Derived
PubMed: PMID 39470878 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis.
Blauvelt A, Eyerich K, Irvine AD, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 39110139 · NCT03738397 (Heads Up) · Dermatitis, Atopic
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Bhatt SP, Rabe KF, Hanania NA, et al. · N Engl J Med · 2024 · Derived
PubMed: PMID 38767614 · NCT04456673 (NOTUS) · Pulmonary Disease, Chronic Obstructive
Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP.
Bachert C, Khan AH, Fokkens WJ, et al. · J Allergy Clin Immunol · 2024 · Derived
PubMed: PMID 39151476 · NCT02898454 (SINUS-52)
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
Bacharier LB, Pavord ID, Maspero JF, et al. · J Allergy Clin Immunol · 2024 · Derived
PubMed: PMID 38272375 · NCT02948959 (VOYAGE) · Asthma
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Bacharier LB, Maspero JF, Katelaris CH, et al. · Lancet Respir Med · 2024 · Derived
PubMed: PMID 37956679 · NCT03560466 · Asthma
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
Bacharier LB, Guilbert TW, Katelaris CH, et al. · J Allergy Clin Immunol Pract · 2024 · Derived
PubMed: PMID 38092225 · NCT02948959 (VOYAGE) · Asthma
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
Armstrong AW, Alexis AF, Blauvelt A, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
PubMed: PMID 38896380 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP.
Fokkens WJ, De Corso E, Backer V, et al. · Rhinology · 2024 · Background
PubMed: PMID 38217529 · NCT07574294 (DREAM-NP) · Asthma
How a hobby farm taught me to set priorities in academia.
Brown B · Nature · 2024 · Background
PubMed: PMID 36198820 · NCT07277322 · Colorectal Neoplasms

2023 (45 papers)

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G, Mollanazar N, Ständer S, et al. · Nat Med · 2023 · Derived
PubMed: PMID 37142763 · NCT04202679 · Neurodermatitis
Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines.
Wechsler ME, Souza-Machado A, Xu C, et al. · J Allergy Clin Immunol Glob · 2023 · Derived
PubMed: PMID 37780074 · NCT02134028 · Asthma
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
Voorberg AN, Kamphuis E, Christoffers WA, et al. · Br J Dermatol · 2023 · Derived
PubMed: PMID 37170922 · NCT04512339 (DUPSHE)
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study.
Tohda Y, Nakamura Y, Fujisawa T, et al. · Allergol Int · 2023 · Derived
PubMed: PMID 36114102 · NCT02134028 · Asthma
Effects of Dupilumab on Mucus Plugging and Ventilation Defects in Patients with Moderate-to-Severe Asthma: A Randomized, Double-Blind, Placebo-Controlled Trial.
Svenningsen S, Kjarsgaard M, Haider E, et al. · Am J Respir Crit Care Med · 2023 · Derived
PubMed: PMID 37603097 · NCT03884842 · Asthma
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S, Kwatra SG, Silverberg JI, et al. · Am J Clin Dermatol · 2023 · Derived
PubMed: PMID 36512175 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL, Silverberg JI, Thyssen JP, et al. · Am J Clin Dermatol · 2023 · Derived
PubMed: PMID 37213005 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Eckert L, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
PubMed: PMID 31641952 · NCT03054428 · Dermatitis, Atopic
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Silverberg JI, Lynde CW, Abuabara K, et al. · Am J Clin Dermatol · 2023 · Derived
PubMed: PMID 36808602 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years.
Siegfried EC, Simpson EL, Cork MJ, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
PubMed: PMID 37480432 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
Siegfried EC, Cork MJ, Katoh N, et al. · Am J Clin Dermatol · 2023 · Derived
PubMed: PMID 37300760 · NCT03345914 · Dermatitis, Atopic
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma.
Sher LD, Passalacqua G, Taillé C, et al. · Ann Allergy Asthma Immunol · 2023 · Derived
PubMed: PMID 36509407 · NCT02134028 · Asthma
Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma.
Sher LD, Corren J, Pavord ID, et al. · J Asthma · 2023 · Derived
PubMed: PMID 36876957 · NCT02134028 · Asthma
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary.
Reich K, Thyssen JP, Blauvelt A, et al. · Immunotherapy · 2023 · Derived
PubMed: PMID 37254941 · NCT04345367 · Dermatitis, Atopic
Dupilumab improves long-term outcomes in patients with uncontrolled, moderate-to-severe GINA-based type 2 asthma, irrespective of allergic status.
Rabe KF, Pavord ID, Busse WW, et al. · Allergy · 2023 · Derived
PubMed: PMID 37073882 · NCT02134028 · Asthma
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.
Pavord ID, Deniz Y, Corren J, et al. · J Allergy Clin Immunol Pract · 2023 · Derived
PubMed: PMID 36535524 · NCT02414854 · Asthma
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose.
Pavord ID, Bourdin A, Papi A, et al. · Allergy · 2023 · Derived
PubMed: PMID 37431558 · NCT02134028 · Asthma
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Papadopoulos NG, Szefler SJ, Bacharier LB, et al. · Allergy · 2023 · Derived
PubMed: PMID 37059696 · NCT02948959 (VOYAGE) · Asthma
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
Paller AS, Silverberg JI, Cork MJ, et al. · JAMA Dermatol · 2023 · Derived
PubMed: PMID 36723913 · NCT02755649 · Dermatitis, Atopic
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paller AS, Siegfried EC, Cork MJ, et al. · Paediatr Drugs · 2023 · Derived
PubMed: PMID 36529811 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.
Mickevicius T, Pink AE, Bhogal M, et al. · Cornea · 2023 · Derived
PubMed: PMID 36525340 · NCT02210780 · Dermatitis, Atopic
Validation of the novel Eosinophilic Esophagitis Impact Questionnaire.
McCann E, Chehade M, Spergel JM, et al. · J Patient Rep Outcomes · 2023 · Derived
PubMed: PMID 38010430 · NCT03633617 · Eosinophilic Esophagitis
Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma.
Maspero JF, Shafazand S, Cole J, et al. · Respir Med · 2023 · Derived
PubMed: PMID 37659435 · NCT02414854 · Asthma
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.
Maspero JF, Bachert C, Martinez FJ, et al. · J Asthma Allergy · 2023 · Derived
PubMed: PMID 37026112 · NCT02898454 (SINUS-52)
The relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP.
Lee SE, Amin N, Mannent LP, et al. · Rhinology · 2023 · Derived
PubMed: PMID 37453138 · NCT02898454 (SINUS-52)
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma.
Jackson DJ, Bacharier LB, Phipatanakul W, et al. · Ann Allergy Asthma Immunol · 2023 · Derived
PubMed: PMID 36958470 · NCT02948959 (VOYAGE) · Asthma
Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps.
Gevaert P, Lee SE, Settipane RA, et al. · Clin Transl Immunology · 2023 · Derived
PubMed: PMID 36721661 · NCT02898454 (SINUS-52)
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.
Fiocchi AG, Phipatanakul W, Zeiger RS, et al. · Eur Respir J · 2023 · Derived
PubMed: PMID 37734856 · NCT02948959 (VOYAGE) · Asthma
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design.
De Prado Gomez L, Pavord I, Busse W, et al. · ERJ Open Res · 2023 · Derived
PubMed: PMID 36891077 · NCT05097287 (ATLAS) · Asthma
Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization.
Corren J, Hanania NA, Busse WW, et al. · Clin Exp Allergy · 2023 · Derived
PubMed: PMID 37752621 · NCT02134028 · Asthma
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Cork MJ, Thaçi D, Eichenfield LF, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
PubMed: PMID 37750994 · NCT02612454 · Dermatitis, Atopic
Baseline Demographics, Comorbidities, Treatment Patterns and Burden of Atopic Dermatitis in Adults and Adolescents from the GLOBOSTAD Long-Term Observational Study.
Calzavara-Pinton P, Čelakovská J, Lapeere H, et al. · Adv Ther · 2023 · Derived
PubMed: PMID 37801232 · NCT03992417 (GLOBOSTAD) · Dermatitis, Atopic
The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response.
Böhner A, Jargosch M, Müller NS, et al. · J Allergy Clin Immunol · 2023 · Derived
PubMed: PMID 37119871 · NCT04600362 (DUPINUM) · Skin Diseases
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.
Bleecker ER, Panettieri RA, Lugogo NL, et al. · J Immunol Res · 2023 · Derived
PubMed: PMID 37901346 · NCT02414854 · Asthma
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Blauvelt A, Wollenberg A, Eichenfield LF, et al. · Adv Ther · 2023 · Derived
PubMed: PMID 36318387 · NCT01949311 · Dermatitis, Atopic
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks.
Blauvelt A, de Bruin-Weller M, Simpson EL, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
PubMed: PMID 34806137 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP, Rabe KF, Hanania NA, et al. · N Engl J Med · 2023 · Derived
PubMed: PMID 37272521 · NCT03930732 (BOREAS) · Pulmonary Disease, Chronic Obstructive
Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps.
Berger P, Menzies-Gow A, Peters AT, et al. · Ann Allergy Asthma Immunol · 2023 · Derived
PubMed: PMID 36356712 · NCT02414854 · Asthma
First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
PubMed: PMID 35129472 · NCT07352566 · Dermatitis, Atopic
Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
Schneider S, Poglitsch K, Morgenstern C, et al. · Eur Respir J · 2023 · Background
PubMed: PMID 36549708 · NCT06398873 (EpiBar)
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
PubMed: PMID 37672566 · NCT07352566 · Dermatitis, Atopic
Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence.
Mimmi S, Lombardo N, Maisano D, et al. · Genes (Basel) · 2023 · Background
PubMed: PMID 36553635 · NCT06188871
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E, Pasquini E, Trimarchi M, et al. · Allergy · 2023 · Background
PubMed: PMID 37203259 · NCT07574294 (DREAM-NP) · Asthma
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus.
Canonica GW, Blasi F, Carpagnano GE, et al. · J Allergy Clin Immunol Pract · 2023 · Background
PubMed: PMID 37558162 · NCT07574294 (DREAM-NP) · Asthma
The Effectiveness of Allergen Immunotherapy in Adult Patients with Atopic Dermatitis Allergic to House Dust Mites.
Bogacz-Piaseczyńska A, Bożek A · Medicina (Kaunas) · 2023 · Background
PubMed: PMID 36676639 · NCT06509243 (DuHDM) · Dermatitis, Atopic

2022 (62 papers)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, et al. · JAMA Dermatol · 2022 · Trial result
PubMed: PMID 34347860 · NCT03738397 (Heads Up) · Dermatitis, Atopic
Neuro-epithelial-ILC2 crosstalk in barrier tissues.
Yin Z, Zhou Y, Turnquist HR, et al. · Trends Immunol · 2022 · Derived
PubMed: PMID 36253275 · NCT03387852 · Asthma
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Wechsler ME, Klion AD, Paggiaro P, et al. · J Allergy Clin Immunol Pract · 2022 · Derived
PubMed: PMID 35636689 · NCT02414854 · Asthma
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME, Ford LB, Maspero JF, et al. · Lancet Respir Med · 2022 · Derived
PubMed: PMID 34597534 · NCT02134028 · Asthma
Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan.
Tohda Y, Matsumoto H, Miyata M, et al. · J Asthma · 2022 · Derived
PubMed: PMID 34752208 · NCT02414854 · Asthma
Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older.
Simpson EL, Paller AS, Siegfried EC, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 34427891 · NCT03345914 · Dermatitis, Atopic
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials.
Silverberg JI, Simpson EL, Guttman-Yassky E, et al. · Dermatitis · 2022 · Derived
PubMed: PMID 33165005 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.
Silverberg JI, Boguniewicz M, Hanifin J, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 36269503 · NCT02277769 (SOLO 2) · Dermatitis, Atopic
Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.
Sher LD, Wechsler ME, Rabe KF, et al. · Chest · 2022 · Derived
PubMed: PMID 35217003 · NCT02134028 · Asthma
Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis.
Rhee CK, Park JW, Park HW, et al. · Allergy Asthma Immunol Res · 2022 · Derived
PubMed: PMID 35255536 · NCT02414854 · Asthma
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K, Thyssen JP, Blauvelt A, et al. · Lancet · 2022 · Derived
PubMed: PMID 35871814 · NCT04345367 · Dermatitis, Atopic
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Reich K, Lio PA, Bissonnette R, et al. · J Allergy Clin Immunol Pract · 2022 · Derived
PubMed: PMID 36108923 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL-1.
Rabe KF, Pavord ID, Castro M, et al. · Eur Respir J · 2022 · Derived
PubMed: PMID 35487538 · NCT02414854 · Asthma
Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.
Rabe KF, FitzGerald JM, Bateman ED, et al. · J Allergy Clin Immunol Pract · 2022 · Derived
PubMed: PMID 36028446 · NCT02414854 · Asthma
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.
Peters AT, Soler ZM, Kern RC, et al. · Clin Exp Allergy · 2022 · Derived
PubMed: PMID 35775319 · NCT02912468 (SINUS-24) · Nasal Polyps
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma.
Papi A, Corren J, Castro M, et al. · Allergy · 2022 · Derived
PubMed: PMID 35899469 · NCT02414854 · Asthma
Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis.
Paller AS, Yosipovitch G, Weidinger S, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 36269504 · NCT03345914 · Dermatitis, Atopic
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
Paller AS, Tan JKL, Bagel J, et al. · Br J Dermatol · 2022 · Derived
PubMed: PMID 34726270 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS, Simpson EL, Siegfried EC, et al. · Lancet · 2022 · Derived
PubMed: PMID 36116481 · NCT03346434 (Liberty AD) · Dermatitis, Atopic
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J, Laidlaw TM, Bachert C, et al. · Allergy · 2022 · Derived
PubMed: PMID 34459002 · NCT02898454 (SINUS-52)
Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics?
Lugogo N, Mohan A · Chest · 2022 · Derived
PubMed: PMID 35809937 · NCT02528214 (VENTURE) · Asthma
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE, Hopkins C, Mullol J, et al. · Allergy · 2022 · Derived
PubMed: PMID 35034364 · NCT02898454 (SINUS-52)
Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps.
Khan AH, Reaney M, Guillemin I, et al. · Laryngoscope · 2022 · Derived
PubMed: PMID 34437720 · NCT02912468 (SINUS-24) · Nasal Polyps
Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab.
Khan AH, Abbe A, Falissard B, et al. · Patient Prefer Adherence · 2022 · Derived
PubMed: PMID 34848949 · NCT01920893 · Nasal Polyps
Pharmacokinetics and Concentration-Response of Dupilumab in Patients With Seasonal Allergic Rhinitis.
Kamal MA, Franchetti Y, Lai CH, et al. · J Clin Pharmacol · 2022 · Derived
PubMed: PMID 34791679 · NCT03558997 · Rhinitis, Allergic
Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis.
Kamal MA, Davis JD, Kovalenko P, et al. · Clin Transl Sci · 2022 · Derived
PubMed: PMID 35986664 · NCT01859988 · Dermatitis, Atopic
Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps.
Hellings PW, Peters AT, Chaker AM, et al. · Int Forum Allergy Rhinol · 2022 · Derived
PubMed: PMID 34911163 · NCT02912468 (SINUS-24) · Nasal Polyps
Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis.
Han JK, Bachert C, Lee SE, et al. · Laryngoscope · 2022 · Derived
PubMed: PMID 34850966 · NCT02912468 (SINUS-24) · Nasal Polyps
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Hamilton JD, Harel S, Swanson BN, et al. · Clin Exp Allergy · 2022 · Derived
PubMed: PMID 34037993 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. · Allergy · 2022 · Derived
PubMed: PMID 34460948 · NCT03359356 · Alopecia Areata
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Griffiths C, de Bruin-Weller M, Deleuran M, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 34142350 · NCT02277769 (SOLO 2) · Dermatitis, Atopic
Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
Geng B, Bachert C, Busse WW, et al. · J Allergy Clin Immunol Pract · 2022 · Derived
PubMed: PMID 34954123 · NCT02414854 · Asthma
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
Fujieda S, Matsune S, Takeno S, et al. · Allergy · 2022 · Derived
PubMed: PMID 33993501 · NCT02898454 (SINUS-52)
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.
Domingo C, Maspero JF, Castro M, et al. · J Allergy Clin Immunol Pract · 2022 · Derived
PubMed: PMID 35398549 · NCT02528214 (VENTURE) · Asthma
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
Dellon ES, Rothenberg ME, Collins MH, et al. · N Engl J Med · 2022 · Derived
PubMed: PMID 36546624 · NCT03633617 · Eosinophilic Esophagitis
Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, et al. · Am J Rhinol Allergy · 2022 · Derived
PubMed: PMID 35837739 · NCT04998604 (EVEREST) · Asthma
Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial.
Corren J, Saini SS, Gagnon R, et al. · J Asthma Allergy · 2022 · Derived
PubMed: PMID 34429614 · NCT03558997 · Rhinitis, Allergic
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
Chuang CC, Guillemin I, Bachert C, et al. · Laryngoscope · 2022 · Derived
PubMed: PMID 34817082 · NCT02898454 (SINUS-52)
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW, Wenzel SE, Casale TB, et al. · Lancet Respir Med · 2022 · Derived
PubMed: PMID 34181876 · NCT02414854 · Asthma
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.
Bourdin A, Virchow JC, Papi A, et al. · Respir Med · 2022 · Derived
PubMed: PMID 36087550 · NCT02414854 · Asthma
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A, Guttman-Yassky E, Paller AS, et al. · Am J Clin Dermatol · 2022 · Derived
PubMed: PMID 35567671 · NCT02407756 · Dermatitis, Atopic
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year.
Blauvelt A, de Bruin-Weller M, Simpson EL, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 34994968 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Bieber T, Simpson EL, Silverberg JI, et al. · Immunotherapy · 2022 · Derived
PubMed: PMID 34775830 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.
Beck LA, Thaçi D, Deleuran M, et al. · J Dermatolog Treat · 2022 · Derived
PubMed: PMID 33557637 · NCT01949311 · Dermatitis, Atopic
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA, Deleuran M, Bissonnette R, et al. · Am J Clin Dermatol · 2022 · Derived
PubMed: PMID 35503163 · NCT01949311 · Dermatitis, Atopic
Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).
Bagel J, Nguyen TQ, Lima H, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 35590038 · NCT03428646 (PROSE) · Dermatitis, Atopic
Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.
Bachert C, Peters AT, Heffler E, et al. · Clin Exp Allergy · 2022 · Derived
PubMed: PMID 35092110 · NCT02898454 (SINUS-52)
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials.
Bachert C, Corren J, Lee SE, et al. · Int Forum Allergy Rhinol · 2022 · Derived
PubMed: PMID 34970860 · NCT02898454 (SINUS-52)
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.
Armstrong A, Blauvelt A, Simpson EL, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 34897582 · NCT02277769 (SOLO 2) · Dermatitis, Atopic
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A, de Bruin-Weller M, Weidinger S, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
PubMed: PMID 35297025 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Distension-contraction profile of peristalsis in patients with nutcracker esophagus.
Zifan A, Muta K, Mittal RK, et al. · Neurogastroenterol Motil · 2022 · Background
PubMed: PMID 33818858 · NCT06665971 · Eosinophilic Esophagitis
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
PubMed: PMID 35788566 · NCT07352566 · Dermatitis, Atopic
Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use.
Spergel BL, Ruffner MA, Godwin BC, et al. · Ann Allergy Asthma Immunol · 2022 · Background
PubMed: PMID 35085819 · NCT05247866 · Eosinophilic Esophagitis
Spanish Asthma Management Guidelines (GEMA) VERSION 5.1. Highlights and Controversies.
Plaza V, Alobid I, Alvarez C, et al. · Arch Bronconeumol · 2022 · Background
PubMed: PMID 34167859 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia
Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
Pellini B, Chaudhuri AA · J Clin Oncol · 2022 · Background
PubMed: PMID 34985936 · NCT07277322 · Colorectal Neoplasms
Distension contraction plots of pharyngeal/esophageal peristalsis: next frontier in the assessment of esophageal motor function.
Omari TI, Zifan A, Cock C, et al. · Am J Physiol Gastrointest Liver Physiol · 2022 · Background
PubMed: PMID 35788152 · NCT06665971 · Eosinophilic Esophagitis
Rhythmic contraction but arrhythmic distension of esophageal peristaltic reflex in patients with dysphagia.
Muta K, Mittal RK, Zifan A, et al. · PLoS One · 2022 · Background
PubMed: PMID 35073388 · NCT06665971 · Eosinophilic Esophagitis
Novel gel bolus to improve impedance-based measurements of esophageal cross-sectional area during primary peristalsis.
Ledgerwood M, Zifan A, Lin W, et al. · Neurogastroenterol Motil · 2022 · Background
PubMed: PMID 33373474 · NCT06665971 · Eosinophilic Esophagitis
Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
Kilty SJ, Lasso A · J Otolaryngol Head Neck Surg · 2022 · Background
PubMed: PMID 35468866 · NCT06683261 (RELIBIO)
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Han JK, Bachert C, Fokkens W, et al. · Lancet Respir Med · 2022 · Background
PubMed: PMID 33872587 · NCT06683261 (RELIBIO)
Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
Fakih M, Sandhu J, Wang C, et al. · JAMA Netw Open · 2022 · Background
PubMed: PMID 35258578 · NCT07277322 · Colorectal Neoplasms
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
Canonica GW, Bourdin A, Peters AT, et al. · J Allergy Clin Immunol Pract · 2022 · Background
PubMed: PMID 35259535 · NCT06188871

2021 (43 papers)

Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
van Toor JJ, van der Mark SC, Kappen JH, et al. · J Asthma · 2021 · Trial result
PubMed: PMID 31999203 · NCT05331755 (RELYonDupi) · Asthma
Defining a Severe Asthma Super-Responder: Findings from a Delphi Process.
Upham JW, Le Lievre C, Jackson DJ, et al. · J Allergy Clin Immunol Pract · 2021 · Trial result
PubMed: PMID 34271216 · NCT05331755 (RELYonDupi) · Asthma
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
Yosipovitch G, de Bruin-Weller M, Armstrong A, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
PubMed: PMID 34714527 · NCT01949311 · Dermatitis, Atopic
Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial.
Wu JJ, Spelman L, Tan JL, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
PubMed: PMID 33511576 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A, Beck LA, Blauvelt A, et al. · Br J Dermatol · 2021 · Derived
PubMed: PMID 31407311 · NCT02277769 (SOLO 2) · Dermatitis, Atopic
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
Wechsler ME, Ruddy MK, Pavord ID, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 34706171 · NCT03387852 · Asthma
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study.
Tohda Y, Nakamura Y, Fujisawa T, et al. · Allergol Int · 2021 · Derived
PubMed: PMID 32444306 · NCT02414854 · Asthma
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL, Silverberg JI, Nosbaum A, et al. · Am J Clin Dermatol · 2021 · Derived
PubMed: PMID 34406619 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Silverberg JI, Yosipovitch G, Simpson EL, et al. · J Am Acad Dermatol · 2021 · Derived
PubMed: PMID 32135208 · NCT03054428 · Dermatitis, Atopic
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Siegfried EC, Bieber T, Simpson EL, et al. · Am J Clin Dermatol · 2021 · Derived
PubMed: PMID 33655423 · NCT03054428 · Dermatitis, Atopic
Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT, Han JK, Hellings P, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
PubMed: PMID 33548517 · NCT02912468 (SINUS-24) · Nasal Polyps
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
Paller AS, Wollenberg A, Siegfried E, et al. · Paediatr Drugs · 2021 · Derived
PubMed: PMID 34462864 · NCT03345914 · Dermatitis, Atopic
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
Maspero JF, Katelaris CH, Busse WW, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
PubMed: PMID 31351189 · NCT02414854 · Asthma
Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST.
Maspero JF, FitzGerald JM, Pavord ID, et al. · Allergy · 2021 · Derived
PubMed: PMID 33905544 · NCT02414854 · Asthma
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM, Bachert C, Amin N, et al. · Ann Allergy Asthma Immunol · 2021 · Derived
PubMed: PMID 33465455 · NCT02912468 (SINUS-24) · Nasal Polyps
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
Katoh N, Kataoka Y, Saeki H, et al. · Br J Dermatol · 2021 · Derived
PubMed: PMID 31564057 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
The impact of fungal allergic sensitization on asthma.
Kao CC, Hanania NA, Parulekar AD, et al. · Curr Opin Pulm Med · 2021 · Derived
PubMed: PMID 33027187 · NCT04442269 · Aspergillosis, Allergic Bronchopulmonary
The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.
Kamal MA, Kovalenko P, Kosloski MP, et al. · Clin Pharmacol Ther · 2021 · Derived
PubMed: PMID 34270797 · NCT03054428 · Dermatitis, Atopic
Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
Hopkins C, Wagenmann M, Bachert C, et al. · Int Forum Allergy Rhinol · 2021 · Derived
PubMed: PMID 33611847 · NCT02898454 (SINUS-52)
The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S, Matsune S, Takeno S, et al. · Laryngoscope · 2021 · Derived
PubMed: PMID 33226139 · NCT02898454 (SINUS-52)
Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort.
Dupin C, Belhadi D, Guilleminault L, et al. · Clin Exp Allergy · 2021 · Derived
PubMed: PMID 32469092 · NCT04022447 (DUPI-France) · Asthma
Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
Corren J, Katelaris CH, Castro M, et al. · Eur Respir J · 2021 · Derived
PubMed: PMID 34266940 · NCT02414854 · Asthma
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.
Corren J, Castro M, O'Riordan T, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
PubMed: PMID 31521831 · NCT02414854 · Asthma
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ, Thaçi D, Eichenfield LF, et al. · Br J Dermatol · 2021 · Derived
PubMed: PMID 31595499 · NCT02407756 · Dermatitis, Atopic
Biologics for chronic rhinosinusitis.
Chong LY, Piromchai P, Sharp S, et al. · Cochrane Database Syst Rev · 2021 · Derived
PubMed: PMID 33710614 · NCT01920893 · Nasal Polyps
Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma.
Busse WW, Paggiaro P, Muñoz X, et al. · Eur Respir J · 2021 · Derived
PubMed: PMID 34326187 · NCT02414854 · Asthma
Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
Bourdin A, Papi AA, Corren J, et al. · Allergy · 2021 · Derived
PubMed: PMID 33010038 · NCT01854047 · Asthma
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
Boguniewicz M, Beck LA, Sher L, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
PubMed: PMID 33453450 · NCT02277769 (SOLO 2) · Dermatitis, Atopic
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 33761207 · NCT03720470 (JADE Compare) · Dermatitis, Atopic
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA, Thaçi D, Deleuran M, et al. · Am J Clin Dermatol · 2021 · Derived
PubMed: PMID 32557382 · NCT01949311 · Dermatitis, Atopic
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A, Simpson EL, Paller AS, et al. · Am J Clin Dermatol · 2021 · Derived
PubMed: PMID 33481203 · NCT02414854 · Asthma
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C, Hellings PW, Mullol J, et al. · Allergy · 2021 · Derived
PubMed: PMID 31306495 · NCT01920893 · Nasal Polyps
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
Bacharier LB, Maspero JF, Katelaris CH, et al. · N Engl J Med · 2021 · Derived
PubMed: PMID 34879449 · NCT02948959 (VOYAGE) · Asthma
COPD-associated miR-145-5p is downregulated in early-decline FEV1 trajectories in childhood asthma.
Tiwari A, Li J, Kho AT, et al. · J Allergy Clin Immunol · 2021 · Background
PubMed: PMID 33385444 · NCT06385236 (EPIPHANY) · Asthma
Eosinophilic Asthma.
Nelson RK, Bush A, Stokes J, et al. · J Allergy Clin Immunol Pract · 2021 · Background
PubMed: PMID 31786254 · NCT06385236 (EPIPHANY) · Asthma
Abnormal Esophageal Distension Profiles in Patients With Functional Dysphagia: A Possible Mechanism of Dysphagia.
Mittal RK, Muta K, Ledgerwood-Lee M, et al. · Gastroenterology · 2021 · Background
PubMed: PMID 33307025 · NCT06665971 · Eosinophilic Esophagitis
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.
Holguin F, Cardet JC, Chung KF, et al. · Eur Respir J · 2021 · Background
PubMed: PMID 31558662 · NCT06385236 (EPIPHANY) · Asthma
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, et al. · J Allergy Clin Immunol · 2021 · Background
PubMed: PMID 32524991 · NCT05246267
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis.
Fokkens W, Van Der Lans R, Reitsma S, et al. · Expert Opin Biol Ther · 2021 · Background
PubMed: PMID 33724109 · NCT06188871
Low regulatory T-cells: A distinct immunological subgroup in minimal change nephrotic syndrome with early relapse following rituximab therapy.
Chan CY, Teo S, Lu L, et al. · Transl Res · 2021 · Background
PubMed: PMID 33812063 · NCT07091175 (SMART-NS) · Nephrotic Syndrome
Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease.
Buchheit KM, Hulse KE · Ann Allergy Asthma Immunol · 2021 · Background
PubMed: PMID 33065294 · NCT05246267
Aspirin-Exacerbated Respiratory Disease: Association Between Patient-Reported Sinus and Asthma Morbidity.
Bergmark RW, Palumbo M, Rahman S, et al. · J Allergy Clin Immunol Pract · 2021 · Background
PubMed: PMID 33307278 · NCT05246267
What is the contribution of IgE to nasal polyposis?
Bachert C, Maurer M, Palomares O, et al. · J Allergy Clin Immunol · 2021 · Background
PubMed: PMID 33757720 · NCT05246267

2020 (30 papers)

Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis.
Stevens WW, Peters AT, Tan BK, et al. · J Allergy Clin Immunol Pract · 2020 · Trial result
PubMed: PMID 31128376 · NCT04430179
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry.
Snelder SM, Weersink EJM, Braunstahl GJ, et al. · Allergy Asthma Clin Immunol · 2020 · Trial result
PubMed: PMID 28769983 · NCT05331755 (RELYonDupi) · Asthma
Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting.
Benjamin MR, Stevens WW, Li N, et al. · J Allergy Clin Immunol Pract · 2020 · Trial result
PubMed: PMID 30368005 · NCT04430179
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M, Simpson EL, Thaçi D, et al. · JAMA Dermatol · 2020 · Derived
PubMed: PMID 31876900 · NCT02395133 (SOLO-CONTINUE) · Dermatitis, Atopic
Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial.
Weyne J, Blauvelt A, de Bruin-Weller M, et al. · Dermatol Ther (Heidelb) · 2020 · Derived
PubMed: PMID 33047298 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials.
Simpson EL · Dermatol Ther (Heidelb) · 2020 · Derived
PubMed: PMID 28503712 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL, Paller AS, Siegfried EC, et al. · JAMA Dermatol · 2020 · Derived
PubMed: PMID 31693077 · NCT03054428 · Dermatitis, Atopic
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI, Simpson EL, Ardeleanu M, et al. · Br J Dermatol · 2020 · Derived
PubMed: PMID 30791102 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS, Bansal A, Simpson EL, et al. · Am J Clin Dermatol · 2020 · Derived
PubMed: PMID 31823222 · NCT03054428 · Dermatitis, Atopic
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.
Laidlaw TM, Mullol J, Fan C, et al. · J Allergy Clin Immunol Pract · 2020 · Derived
PubMed: PMID 30954643 · NCT01920893 · Nasal Polyps
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K, Swanson BN, Mannent LP, et al. · Allergy · 2020 · Derived
PubMed: PMID 30488542 · NCT01920893 · Nasal Polyps
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I, Dellon ES, Hamilton JD, et al. · Gastroenterology · 2020 · Derived
PubMed: PMID 31593702 · NCT02379052 · Eosinophilic Esophagitis
Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.
Corren J, Castro M, Ford LB, et al. · Ann Allergy Asthma Immunol · 2020 · Derived
PubMed: PMID 31075309 · NCT01854047 · Asthma
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.
Callewaert C, Nakatsuji T, Knight R, et al. · J Invest Dermatol · 2020 · Derived
PubMed: PMID 31252032 · NCT01979016 · Dermatitis, Atopic
Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Boyle JV, Lam K, Han JK, et al. · Immunotherapy · 2020 · Derived
PubMed: PMID 32075470 · NCT01920893 · Nasal Polyps
Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis.
Takeda K, Sakakibara S, Yamashita K, et al. · J Allergy Clin Immunol · 2020 · Background
PubMed: PMID 30053529 · NCT05246267
Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.
Shah SJ, Abuzeid WM, Ponduri A, et al. · Int Forum Allergy Rhinol · 2020 · Background
PubMed: PMID 31569308 · NCT05246267
Time's up to adopt a biopsychosocial model to address racial and ethnic disparities in asthma outcomes.
Matsui EC, Adamson AS, Peng RD, et al. · J Allergy Clin Immunol · 2020 · Background
PubMed: PMID 30940518 · NCT05246267
High-frequency ultrasound imaging of the anal sphincter muscles in normal subjects and patients with fecal incontinence.
Ledgerwood-Lee M, Zifan A, Kunkel DC, et al. · Neurogastroenterol Motil · 2020 · Background
PubMed: PMID 30680849 · NCT06665971 · Eosinophilic Esophagitis
Atopic dermatitis.
Langan SM, Irvine AD, Weidinger S, et al. · Lancet · 2020 · Background
PubMed: PMID 32738956 · NCT06116526 · Dermatitis, Atopic
Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.
Kowalski ML, Agache I, Bavbek S, et al. · Allergy · 2020 · Background
PubMed: PMID 30216468 · NCT06683261 (RELIBIO)
Sinus Surgery Is Associated with a Decrease in Aspirin-Induced Reaction Severity in Patients with Aspirin Exacerbated Respiratory Disease.
Jerschow E, Edin ML, Chi Y, et al. · J Allergy Clin Immunol Pract · 2020 · Background
PubMed: PMID 30580047 · NCT05246267
Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD.
Huang GX, Palumbo ML, Singer JI, et al. · J Allergy Clin Immunol Pract · 2020 · Background
PubMed: PMID 30877073 · NCT05246267
Staphylococcus aureus internalization in mast cells in nasal polyps: Characterization of interactions and potential mechanisms.
Hayes SM, Biggs TC, Goldie SP, et al. · J Allergy Clin Immunol · 2020 · Background
PubMed: PMID 31254531 · NCT05246267
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
Fokkens WJ, Lund VJ, Hopkins C, et al. · Rhinology · 2020 · Background
PubMed: PMID 32077450 · NCT06750471 · Nasal Polyps
EUFOREA consensus on biologics for CRSwNP with or without asthma.
Fokkens WJ, Lund V, Bachert C, et al. · Allergy · 2020 · Background
PubMed: PMID 31090937 · NCT06750471 · Nasal Polyps
Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.
Fitzpatrick AM, Gillespie SE, Mauger DT, et al. · J Allergy Clin Immunol · 2020 · Background
PubMed: PMID 30635198 · NCT05246267
Endotypes of chronic rhinosinusitis: Impact on management.
Cardell LO, Stjärne P, Jonstam K, et al. · J Allergy Clin Immunol · 2020 · Background
PubMed: PMID 32001254 · NCT05246267
Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management.
Bleecker ER, Menzies-Gow AN, Price DB, et al. · Am J Respir Crit Care Med · 2020 · Background
PubMed: PMID 31525297 · NCT06385236 (EPIPHANY) · Asthma
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma.
Bachert C, Hellings PW, Mullol J, et al. · J Allergy Clin Immunol Pract · 2020 · Background
PubMed: PMID 30928658 · NCT05246267

2019 (17 papers)

Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
Weinstein SF, Katial R, Jayawardena S, et al. · J Allergy Clin Immunol · 2019 · Derived
PubMed: PMID 29355679 · NCT02414854 · Asthma
Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
Tsianakas A, Luger TA, Radin A, et al. · Br J Dermatol · 2019 · Derived
PubMed: PMID 28845523 · NCT01548404 · Dermatitis, Atopic
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E, Bissonnette R, Ungar B, et al. · J Allergy Clin Immunol · 2019 · Derived
PubMed: PMID 30194992 · NCT01979016 · Dermatitis, Atopic
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Eichenfield LF, Bieber T, Beck LA, et al. · Am J Clin Dermatol · 2019 · Derived
PubMed: PMID 31066001 · NCT02755649 · Dermatitis, Atopic
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors.
de Bruin-Weller M, Graham NMH, Pirozzi G, et al. · Br J Dermatol · 2019 · Derived
PubMed: PMID 29336016 · NCT02755649 · Dermatitis, Atopic
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.
Davis JD, Bansal A, Hassman D, et al. · Clin Pharmacol Ther · 2019 · Derived
PubMed: PMID 29498038 · NCT02647086 · Dermatitis, Atopic
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma.
Corren J, Castro M, Chanez P, et al. · Ann Allergy Asthma Immunol · 2019 · Derived
PubMed: PMID 30138668 · NCT01854047 · Asthma
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.
Busse WW, Maspero JF, Rabe KF, et al. · Adv Ther · 2019 · Derived
PubMed: PMID 29725983 · NCT02414854 · Asthma
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, Han JK, Desrosiers M, et al. · Lancet · 2019 · Derived
PubMed: PMID 31543428 · NCT02898454 (SINUS-52)
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
Alexis AF, Rendon M, Silverberg JI, et al. · J Drugs Dermatol · 2019 · Derived
PubMed: PMID 31424712 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Topographical plots of esophageal distension and contraction: effects of posture on esophageal peristalsis and bolus transport.
Zifan A, Song HJ, Youn YH, et al. · Am J Physiol Gastrointest Liver Physiol · 2019 · Background
PubMed: PMID 30676774 · NCT06665971 · Eosinophilic Esophagitis
Biphasic activation of complement and fibrinolysis during the human nasal allergic response.
Thwaites RS, Gunawardana NC, Broich V, et al. · J Allergy Clin Immunol · 2019 · Background
PubMed: PMID 29427640 · NCT04430179
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F, Sofiya L, Sykiotis GP, et al. · Nat Rev Clin Oncol · 2019 · Background
PubMed: PMID 31092901 · NCT07277322 · Colorectal Neoplasms
Gene-environment interaction between an IL4R variant and school endotoxin exposure contributes to asthma symptoms in inner-city children.
Lai PS, Massoud AH, Xia M, et al. · J Allergy Clin Immunol · 2019 · Background
PubMed: PMID 28943468 · NCT03694158 (IDEA) · Asthma
The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps.
Khan A, Vandeplas G, Huynh TMT, et al. · Rhinology · 2019 · Background
PubMed: PMID 29911211 · NCT06683261 (RELIBIO)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC, Orlowski RJ, Xu X, et al. · Nat Med · 2019 · Background
PubMed: PMID 30804515 · NCT07277322 · Colorectal Neoplasms
EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis.
Fokkens W, Desrosiers M, Harvey R, et al. · Rhinology · 2019 · Background
PubMed: PMID 30810118 · NCT05246267

2018 (18 papers)

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF, Nair P, Brusselle G, et al. · N Engl J Med · 2018 · Trial result
PubMed: PMID 29782224 · NCT05331755 (RELYonDupi) · Asthma
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, et al. · N Engl J Med · 2018 · Trial result
PubMed: PMID 29782217 · NCT02414854 · Asthma
A survey of aspirin desensitization practices among allergists and fellows in training in the United States.
Waldram JD, White AA · J Allergy Clin Immunol Pract · 2018 · Background
PubMed: PMID 27452889 · NCT03595488
Development and validation of the brief esophageal dysphagia questionnaire.
Taft TH, Riehl M, Sodikoff JB, et al. · Neurogastroenterol Motil · 2018 · Background
PubMed: PMID 27380834 · NCT06665971 · Eosinophilic Esophagitis
Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.
Stevens WW, Peters AT, Hirsch AG, et al. · J Allergy Clin Immunol Pract · 2018 · Background
PubMed: PMID 28286156 · NCT06683261 (RELIBIO)
Asthma.
Papi A, Brightling C, Pedersen SE, et al. · Lancet · 2018 · Background
PubMed: PMID 29273246 · NCT06385236 (EPIPHANY) · Asthma
Atopic Dermatitis, Depression, and Suicidality.
Nicholas MN, Gooderham MJ · J Cutan Med Surg · 2018 · Background
PubMed: PMID 28300443 · NCT03667014 · Dermatitis, Atopic
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V, Fessler J, Bao R, et al. · Science · 2018 · Background
PubMed: PMID 29302014 · NCT07277322 · Colorectal Neoplasms
Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.
Jerschow E, Edin ML, Pelletier T, et al. · J Allergy Clin Immunol Pract · 2018 · Background
PubMed: PMID 28159558 · NCT05246267
Systemic Predictors of Eosinophilic Chronic Rhinosinusitis.
Ho J, Hamizan AW, Alvarado R, et al. · Am J Rhinol Allergy · 2018 · Background
PubMed: PMID 29862828 · NCT04430179
The National Biome Initiative: An allergy perspective.
Furuta GT, Aceves SS · J Allergy Clin Immunol · 2018 · Background
PubMed: PMID 28257973 · NCT06665971 · Eosinophilic Esophagitis
A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials.
Fuhlbrigge AL, Bengtsson T, Peterson S, et al. · Lancet Respir Med · 2018 · Background
PubMed: PMID 28583396 · NCT06385236 (EPIPHANY) · Asthma
Research Gaps in Quality of Life and Economic Burden of Atopic Dermatitis: The National Eczema Association Burden of Disease Audit.
Drucker AM, Wang AR, Qureshi AA, et al. · JAMA Dermatol · 2018 · Background
PubMed: PMID 27305113 · NCT03667014 · Dermatitis, Atopic
New Biologics for Asthma.
Drazen JM, Harrington D · N Engl J Med · 2018 · Background
PubMed: PMID 29782236 · NCT06385236 (EPIPHANY) · Asthma
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference.
Dellon ES, Liacouras CA, Molina-Infante J, et al. · Gastroenterology · 2018 · Background
PubMed: PMID 30009819 · NCT05247866 · Eosinophilic Esophagitis
Epidemiology and Natural History of Eosinophilic Esophagitis.
Dellon ES, Hirano I · Gastroenterology · 2018 · Background
PubMed: PMID 28774845 · NCT06665971 · Eosinophilic Esophagitis
ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests.
Coates AL, Wanger J, Cockcroft DW, et al. · Eur Respir J · 2018 · Background
PubMed: PMID 28461290 · NCT06385236 (EPIPHANY) · Asthma
The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M, Nakamura M, Zhu TH, et al. · J Dermatolog Treat · 2018 · Background
PubMed: PMID 28042711 · NCT03667014 · Dermatitis, Atopic

2017 (14 papers)

Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania.
Wang X, Zhang N, Bo M, et al. · J Allergy Clin Immunol · 2017 · Trial result
PubMed: PMID 27544740 · NCT04430179
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL, Gadkari A, Worm M, et al. · J Am Acad Dermatol · 2017 · Trial result
PubMed: PMID 27268421 · NCT01859988 · Dermatitis, Atopic
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, et al. · N Engl J Med · 2017 · Trial result
PubMed: PMID 27690741 · NCT02277743 (SOLO 1) · Dermatitis, Atopic
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. · Lancet · 2017 · Derived
PubMed: PMID 28478972 · NCT02260986 (CHRONOS) · Dermatitis, Atopic
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.
Tomassen P, Vandeplas G, Van Zele T, et al. · J Allergy Clin Immunol · 2017 · Background
PubMed: PMID 26949058 · NCT06683261 (RELIBIO)
Evolving Concepts in Atopic Dermatitis.
Sidbury R, Khorsand K · Curr Allergy Asthma Rep · 2017 · Background
PubMed: PMID 28555328 · NCT03667014 · Dermatitis, Atopic
Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma.
Phipatanakul W, Mauger DT, Sorkness RL, et al. · Am J Respir Crit Care Med · 2017 · Background
PubMed: PMID 27967215 · NCT06385236 (EPIPHANY) · Asthma
Race is associated with differences in airway inflammation in patients with asthma.
Nyenhuis SM, Krishnan JA, Berry A, et al. · J Allergy Clin Immunol · 2017 · Background
PubMed: PMID 28069248 · NCT05246267
Regulation and dysregulation of esophageal peristalsis by the integrated function of circular and longitudinal muscle layers in health and disease.
Mittal RK · Am J Physiol Gastrointest Liver Physiol · 2017 · Background
PubMed: PMID 27445346 · NCT06665971 · Eosinophilic Esophagitis
An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells.
Massoud AH, Charbonnier LM, Lopez D, et al. · Nat Med · 2017 · Background
PubMed: PMID 27479084 · NCT03694158 (IDEA) · Asthma
African American Patients with Chronic Rhinosinusitis Have a Distinct Phenotype of Polyposis Associated with Increased Asthma Hospitalization.
Mahdavinia M, Benhammuda M, Codispoti CD, et al. · J Allergy Clin Immunol Pract · 2017 · Background
PubMed: PMID 26868728 · NCT05246267
A Recently Established Murine Model of Nasal Polyps Demonstrates Activation of B Cells, as Occurs in Human Nasal Polyps.
Kim DY, Lee SH, Carter RG, et al. · Am J Respir Cell Mol Biol · 2017 · Background
PubMed: PMID 27163839 · NCT04430179
Gene expression profiling of asthma phenotypes demonstrates molecular signatures of atopy and asthma control.
Howrylak JA, Moll M, Weiss ST, et al. · J Allergy Clin Immunol · 2017 · Background
PubMed: PMID 26792209 · NCT06385236 (EPIPHANY) · Asthma
The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association.
Drucker AM, Wang AR, Li WQ, et al. · J Invest Dermatol · 2017 · Background
PubMed: PMID 27616422 · NCT06116526 · Dermatitis, Atopic

2016 (13 papers)

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, Castro M, Corren J, et al. · Lancet · 2016 · Trial result
PubMed: PMID 27130691 · NCT01854047 · Asthma
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Thaçi D, Simpson EL, Beck LA, et al. · Lancet · 2016 · Trial result
PubMed: PMID 26454361 · NCT01859988 · Dermatitis, Atopic
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.
Simpson EL, Bieber T, Eckert L, et al. · J Am Acad Dermatol · 2016 · Trial result
PubMed: PMID 26777100 · NCT01859988 · Dermatitis, Atopic
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
Bachert C, Mannent L, Naclerio RM, et al. · JAMA · 2016 · Trial result
PubMed: PMID 26836729 · NCT01920893 · Nasal Polyps
Measurement of peak esophageal luminal cross-sectional area utilizing nadir intraluminal impedance.
Zifan A, Ledgerwood-Lee M, Mittal RK, et al. · Neurogastroenterol Motil · 2016 · Background
PubMed: PMID 25930157 · NCT06665971 · Eosinophilic Esophagitis
Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study.
Tokunaga T, Sakashita M, Haruna T, et al. · Allergy · 2016 · Background
PubMed: PMID 25945591 · NCT04430179
Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease.
Ta V, White AA · J Allergy Clin Immunol Pract · 2016 · Background
PubMed: PMID 25858054 · NCT03595488
A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial.
Sommer DD, Rotenberg BW, Sowerby LJ, et al. · Int Forum Allergy Rhinol · 2016 · Background
PubMed: PMID 26751262 · NCT03595488
Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids.
Rajan J, Newbury RO, Anilkumar A, et al. · J Allergy Clin Immunol · 2016 · Background
PubMed: PMID 26233926 · NCT06665971 · Eosinophilic Esophagitis
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.
Orlandi RR, Kingdom TT, Hwang PH, et al. · Int Forum Allergy Rhinol · 2016 · Background
PubMed: PMID 26889651 · NCT05246267
The Sinonasal Outcome Test 22 score in persons without chronic rhinosinusitis.
Lange B, Thilsing T, Baelum J, et al. · Clin Otolaryngol · 2016 · Background
PubMed: PMID 26095903 · NCT03595488
Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.
Laidlaw TM, Boyce JA · N Engl J Med · 2016 · Background
PubMed: PMID 26840139 · NCT03595488
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
PubMed: PMID 25904741 · NCT07352566 · Dermatitis, Atopic

2015 (16 papers)

The prevalence of severe refractory asthma.
Hekking PW, Wener RR, Amelink M, et al. · J Allergy Clin Immunol · 2015 · Trial result
PubMed: PMID 25441637 · NCT05331755 (RELYonDupi) · Asthma
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. · J Allergy Clin Immunol · 2015 · Trial result
PubMed: PMID 25482871 · NCT01385657 · Dermatitis, Atopic
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
Świerczyńska-Krępa M, Sanak M, Bochenek G, et al. · J Allergy Clin Immunol · 2015 · Background
PubMed: PMID 24767875 · NCT03595488
Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study.
Sommer DD, Hoffbauer S, Au M, et al. · Otolaryngol Head Neck Surg · 2015 · Background
PubMed: PMID 25344589 · NCT03595488
Glucocorticoid genes and the developmental origins of asthma susceptibility and treatment response.
Sharma S, Kho AT, Chhabra D, et al. · Am J Respir Cell Mol Biol · 2015 · Background
PubMed: PMID 25192440 · NCT06385236 (EPIPHANY) · Asthma
Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.
Rajan JP, Wineinger NE, Stevenson DD, et al. · J Allergy Clin Immunol · 2015 · Background
PubMed: PMID 25282015 · NCT03595488
Genetic ancestry influences asthma susceptibility and lung function among Latinos.
Pino-Yanes M, Thakur N, Gignoux CR, et al. · J Allergy Clin Immunol · 2015 · Background
PubMed: PMID 25301036 · NCT05246267
The hand eczema proteome: imbalance of epidermal barrier proteins.
Molin S, Merl J, Dietrich KA, et al. · Br J Dermatol · 2015 · Background
PubMed: PMID 25244099 · NCT03861455 (DUPECZEMAIN)
Characterization of atopic skin and the effect of a hyperforin-rich cream by laser scanning microscopy.
Meinke MC, Richter H, Kleemann A, et al. · J Biomed Opt · 2015 · Background
PubMed: PMID 25467783 · NCT05265234 · Dermatitis, Atopic
Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches.
Leung DY, Guttman-Yassky E · J Allergy Clin Immunol · 2015 · Background
PubMed: PMID 25282559 · NCT05265234 · Dermatitis, Atopic
Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.
Hirano I, Aceves SS · Gastroenterol Clin North Am · 2015 · Background
PubMed: PMID 24813517 · NCT06665971 · Eosinophilic Esophagitis
[Hand eczema : disability and impact].
Halioua B · Ann Dermatol Venereol · 2015 · Background
PubMed: PMID 24953620 · NCT03861455 (DUPECZEMAIN)
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy.
Fowler JF, Graff O, Hamedani AG, et al. · J Drugs Dermatol · 2015 · Background
PubMed: PMID 25607554 · NCT03861455 (DUPECZEMAIN)
Clinical presentation of eosinophilic esophagitis in adults.
Falk GW · Gastroenterol Clin North Am · 2015 · Background
PubMed: PMID 24813512 · NCT06665971 · Eosinophilic Esophagitis
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
Esmaeilzadeh H, Nabavi M, Aryan Z, et al. · Clin Immunol · 2015 · Background
PubMed: PMID 26083948 · NCT03595488
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
Cho KS, Soudry E, Psaltis AJ, et al. · Otolaryngol Head Neck Surg · 2015 · Background
PubMed: PMID 25118195 · NCT03595488

2014 (10 papers)

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA, Thaçi D, Hamilton JD, et al. · N Engl J Med · 2014 · Trial result
PubMed: PMID 25006719 · NCT01639040 · Dermatitis, Atopic
Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?
Tang TS, Bieber T, Williams HC, et al. · J Allergy Clin Immunol · 2014 · Background
PubMed: PMID 24655575 · NCT05265234 · Dermatitis, Atopic
Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before bronchodilation.
Svenningsen S, Kirby M, Starr D, et al. · J Magn Reson Imaging · 2014 · Background
PubMed: PMID 23589465 · NCT03884842 · Asthma
Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis.
Nicodème F, Hirano I, Chen J, et al. · Clin Gastroenterol Hepatol · 2014 · Background
PubMed: PMID 23591279 · NCT06665971 · Eosinophilic Esophagitis
Calculating sample size estimates for RNA sequencing data.
Hart SN, Therneau TM, Zhang Y, et al. · J Comput Biol · 2014 · Background
PubMed: PMID 23961961 · NCT06385236 (EPIPHANY) · Asthma
Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).
García-Río F, Calle M, Burgos F, et al. · Arch Bronconeumol · 2014 · Background
PubMed: PMID 23726118 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia
Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis.
Dellon ES, Irani AM, Hill MR, et al. · Aliment Pharmacol Ther · 2014 · Background
PubMed: PMID 23837796 · NCT06665971 · Eosinophilic Esophagitis
Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids.
Cortesi PA, Scalone L, Belisari A, et al. · Contact Dermatitis · 2014 · Background
PubMed: PMID 24102212 · NCT03861455 (DUPECZEMAIN)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
Chung KF, Wenzel SE, Brozek JL, et al. · Eur Respir J · 2014 · Background
PubMed: PMID 24337046 · NCT06385236 (EPIPHANY) · Asthma
British guideline on the management of asthma.
British Thoracic Society, Scottish Intercollegiate Guidelines Network · Thorax · 2014 · Background
PubMed: PMID 25323740 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia

2013 (9 papers)

Dupilumab in persistent asthma with elevated eosinophil levels.
Wenzel S, Ford L, Pearlman D, et al. · N Engl J Med · 2013 · Trial result
PubMed: PMID 23688323 · NCT01312961 · Asthma
Flow cytometry analysis of leukocytes in induced sputum from asthmatic patients.
Vidal S, Bellido-Casado J, Granel C, et al. · Immunobiology · 2013 · Background
PubMed: PMID 22204819 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia
African ancestry is a risk factor for asthma and high total IgE levels in African admixed populations.
Vergara C, Murray T, Rafaels N, et al. · Genet Epidemiol · 2013 · Background
PubMed: PMID 23554133 · NCT05246267
Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
Mullol J, Picado C · Immunol Allergy Clin North Am · 2013 · Background
PubMed: PMID 23639706 · NCT03595488
Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites.
Higashi N, Taniguchi M, Mita H, et al. · Allergol Int · 2013 · Background
PubMed: PMID 22627848 · NCT05246267
CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens.
Hayworth JL, Mazzuca DM, Maleki Vareki S, et al. · Immunol Cell Biol · 2013 · Background
PubMed: PMID 22041925 · NCT05246267
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.
Gevaert P, Calus L, Van Zele T, et al. · J Allergy Clin Immunol · 2013 · Background
PubMed: PMID 23021878 · NCT04430179
Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.
Fruth K, Pogorzelski B, Schmidtmann I, et al. · Allergy · 2013 · Background
PubMed: PMID 23464577 · NCT03595488
Influence of asthma on quality of life and clinical characteristics of patients with nasal polyposis.
Dudvarski Z, Djukic V, Janosevic L, et al. · Eur Arch Otorhinolaryngol · 2013 · Background
PubMed: PMID 23135235 · NCT06683261 (RELIBIO)

2012 (7 papers)

The dynamics of T cells during persistent Staphylococcus aureus infection: from antigen-reactivity to in vivo anergy.
Ziegler C, Goldmann O, Hobeika E, et al. · EMBO Mol Med · 2012 · Background
PubMed: PMID 21887823 · NCT05246267
Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults.
Hu Y, Cao PP, Liang GT, et al. · Laryngoscope · 2012 · Background
PubMed: PMID 22252861 · NCT04430179
Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis.
Higashi N, Mita H, Yamaguchi H, et al. · J Allergy Clin Immunol · 2012 · Background
PubMed: PMID 22018904 · NCT05246267
Asthma outcomes: exacerbations.
Fuhlbrigge A, Peden D, Apter AJ, et al. · J Allergy Clin Immunol · 2012 · Background
PubMed: PMID 22386508 · NCT06385236 (EPIPHANY) · Asthma
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.
Fokkens WJ, Lund VJ, Mullol J, et al. · Rhinology · 2012 · Background
PubMed: PMID 22469599 · NCT06683261 (RELIBIO)
Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'.
Bachert C, Zhang N · J Intern Med · 2012 · Background
PubMed: PMID 22640264 · NCT03595488
Eosinophilic esophagitis: rapidly advancing insights.
Abonia JP, Rothenberg ME · Annu Rev Med · 2012 · Background
PubMed: PMID 22034864 · NCT06665971 · Eosinophilic Esophagitis

2011 (4 papers)

Mucosal tissue polyclonal IgE is functional in response to allergen and SEB.
Zhang N, Holtappels G, Gevaert P, et al. · Allergy · 2011 · Background
PubMed: PMID 20659077 · NCT06683261 (RELIBIO)
Pathogenesis of chronic rhinosinusitis: inflammation.
Van Crombruggen K, Zhang N, Gevaert P, et al. · J Allergy Clin Immunol · 2011 · Background
PubMed: PMID 21868076 · NCT06750471 · Nasal Polyps
Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study.
Hastan D, Fokkens WJ, Bachert C, et al. · Allergy · 2011 · Background
PubMed: PMID 21605125 · NCT06683261 (RELIBIO)
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
Gevaert P, Van Bruaene N, Cattaert T, et al. · J Allergy Clin Immunol · 2011 · Background
PubMed: PMID 21958585 · NCT04430179

2010 (6 papers)

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.
Moore WC, Meyers DA, Wenzel SE, et al. · Am J Respir Crit Care Med · 2010 · Background
PubMed: PMID 19892860 · NCT06385236 (EPIPHANY) · Asthma
Psychometric validity of the 22-item Sinonasal Outcome Test.
Hopkins C, Gillett S, Slack R, et al. · Clin Otolaryngol · 2010 · Background
PubMed: PMID 19793277 · NCT03595488
Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers.
Higashi N, Mita H, Ono E, et al. · J Allergy Clin Immunol · 2010 · Background
PubMed: PMID 20304469 · NCT05246267
A pilot study of the SNOT 22 score in adults with no sinonasal disease.
Gillett S, Hopkins C, Slack R, et al. · Clin Otolaryngol · 2010 · Background
PubMed: PMID 19793280 · NCT03595488
Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Dohil R, Newbury R, Fox L, et al. · Gastroenterology · 2010 · Background
PubMed: PMID 20457157 · NCT06665971 · Eosinophilic Esophagitis
Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis.
Blanchard C, Stucke EM, Burwinkel K, et al. · J Immunol · 2010 · Background
PubMed: PMID 20208004 · NCT06665971 · Eosinophilic Esophagitis

2009 (4 papers)

Predictors of bronchial hyperresponsiveness in chronic rhinosinusitis with nasal polyp.
Han DH, Kim SW, Cho SH, et al. · Allergy · 2009 · Trial result
PubMed: PMID 19120071 · NCT04430179
Dysfunction of the longitudinal muscles of the oesophagus in eosinophilic oesophagitis.
Korsapati H, Babaei A, Bhargava V, et al. · Gut · 2009 · Background
PubMed: PMID 19136515 · NCT06665971 · Eosinophilic Esophagitis
Detection of Staphylococcus aureus in nasal tissue with peptide nucleic acid-fluorescence in situ hybridization.
Corriveau MN, Zhang N, Holtappels G, et al. · Am J Rhinol Allergy · 2009 · Background
PubMed: PMID 19807976 · NCT05246267
Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.
Aceves SS, Ackerman SJ · Immunol Allergy Clin North Am · 2009 · Background
PubMed: PMID 19141355 · NCT06665971 · Eosinophilic Esophagitis

2008 (5 papers)

Validation of the Spanish version of the Asthma Control Test (ACT).
Vega JM, Badia X, Badiola C, et al. · J Asthma · 2008 · Background
PubMed: PMID 18097865 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia
Latino populations: a unique opportunity for epidemiological research of asthma.
Salari K, Burchard EG · Paediatr Perinat Epidemiol · 2008 · Background
PubMed: PMID 17935571 · NCT05246267
Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps.
Patou J, Gevaert P, Van Zele T, et al. · J Allergy Clin Immunol · 2008 · Background
PubMed: PMID 17980412 · NCT03595488
Esophageal dysmotility in patients who have eosinophilic esophagitis.
Nurko S, Rosen R · Gastrointest Endosc Clin N Am · 2008 · Background
PubMed: PMID 18061103 · NCT06665971 · Eosinophilic Esophagitis
Physiology of normal esophageal motility.
Goyal RK, Chaudhury A · J Clin Gastroenterol · 2008 · Background
PubMed: PMID 18364578 · NCT06665971 · Eosinophilic Esophagitis

2007 (4 papers)

Medical and surgical considerations in patients with Samter's triad.
McMains KC, Kountakis SE · Am J Rhinol · 2007 · Background
PubMed: PMID 17181095 · NCT05246267
Manometric findings in adult eosinophilic oesophagitis: a study of 12 cases.
Lucendo AJ, Castillo P, Martín-Chávarri S, et al. · Eur J Gastroenterol Hepatol · 2007 · Background
PubMed: PMID 17413294 · NCT06665971 · Eosinophilic Esophagitis
Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats.
Lai KW, Wei CL, Tan LK, et al. · J Am Soc Nephrol · 2007 · Background
PubMed: PMID 17429054 · NCT07091175 (SMART-NS) · Nephrotic Syndrome
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
Kim JE, Kountakis SE · Ear Nose Throat J · 2007 · Background
PubMed: PMID 17702319 · NCT05246267

2006 (4 papers)

Standardisation of spirometry.
Miller MR, Hankinson J, Brusasco V, et al. · Eur Respir J · 2006 · Background
PubMed: PMID 16055882 · NCT03595488
Complications of surgery for nasal polyposis and chronic rhinosinusitis: the results of a national audit in England and Wales.
Hopkins C, Browne JP, Slack R, et al. · Laryngoscope · 2006 · Background
PubMed: PMID 16885760 · NCT04430179
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.
Gevaert P, Lang-Loidolt D, Lackner A, et al. · J Allergy Clin Immunol · 2006 · Background
PubMed: PMID 17088140 · NCT04430179
ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.
American Thoracic Society, European Respiratory Society · Am J Respir Crit Care Med · 2006 · Background
PubMed: PMID 15817806 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia

2005 (3 papers)

Sensory and motor function of the esophagus: lessons from ultrasound imaging.
Mittal RK, Liu J, Puckett JL, et al. · Gastroenterology · 2005 · Background
PubMed: PMID 15685559 · NCT06665971 · Eosinophilic Esophagitis
Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A, Qaqish BF, Schell MJ, et al. · Biometrics · 2005 · Background
PubMed: PMID 16011702 · NCT07277322 · Colorectal Neoplasms
Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma.
Borish L, Chipps B, Deniz Y, et al. · Ann Allergy Asthma Immunol · 2005 · Background
PubMed: PMID 16200815 · NCT05246267

2004 (7 papers)

Collection of nasal secretions for immunological analysis.
Watelet JB, Gevaert P, Holtappels G, et al. · Eur Arch Otorhinolaryngol · 2004 · Background
PubMed: PMID 14551791 · NCT06188871
Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.
Van Zele T, Gevaert P, Watelet JB, et al. · J Allergy Clin Immunol · 2004 · Background
PubMed: PMID 15480349 · NCT05246267
An alternative technique for nasal biopsy.
Thornton MA, Walshe P, Costello RW, et al. · Laryngoscope · 2004 · Background
PubMed: PMID 15179213 · NCT05246267
Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma.
Suh YJ, Yoon SH, Sampson AP, et al. · Clin Exp Allergy · 2004 · Background
PubMed: PMID 15298569 · NCT05246267
Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship.
Pérez-Novo CA, Kowalski ML, Kuna P, et al. · Int Arch Allergy Immunol · 2004 · Background
PubMed: PMID 14976394 · NCT05246267
Development of the asthma control test: a survey for assessing asthma control.
Nathan RA, Sorkness CA, Kosinski M, et al. · J Allergy Clin Immunol · 2004 · Background
PubMed: PMID 14713908 · NCT03595488
Symptom hypersensitivity to acid infusion is associated with hypersensitivity of esophageal contractility.
Bhalla V, Liu J, Puckett JL, et al. · Am J Physiol Gastrointest Liver Physiol · 2004 · Background
PubMed: PMID 14977636 · NCT06665971 · Eosinophilic Esophagitis

2003 (2 papers)

Sputum induction.
Paggiaro PL, Chanez P, Holz O, et al. · Eur Respir J Suppl · 2003 · Background
PubMed: PMID 12361361 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia
Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.
Berges-Gimeno MP, Simon RA, Stevenson DD, et al. · J Allergy Clin Immunol · 2003 · Background
PubMed: PMID 12532116 · NCT03595488

2001 (3 papers)

Esophagitis-related esophageal shortening in opossum is associated with longitudinal muscle hyperresponsiveness.
White RJ, Zhang Y, Morris GP, et al. · Am J Physiol Gastrointest Liver Physiol · 2001 · Background
PubMed: PMID 11171629 · NCT06665971 · Eosinophilic Esophagitis
Use of the Rhinosinusitis Disability Index (RSDI) in rhinologic disease.
Senior BA, Glaze C, Benninger MS, et al. · Am J Rhinol · 2001 · Background
PubMed: PMID 11258649 · NCT06750471 · Nasal Polyps
Noninvasive methods to measure airway inflammation: future considerations.
Magnussen H, Holz O, Sterk PJ, et al. · Eur Respir J · 2001 · Background
PubMed: PMID 11292124 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia

2000 (1 paper)

Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999.
Crapo RO, Casaburi R, Coates AL, et al. · Am J Respir Crit Care Med · 2000 · Background
PubMed: PMID 10619836 · NCT03884842 · Asthma

1999 (3 papers)

Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse.
Yap HK, Cheung W, Murugasu B, et al. · J Am Soc Nephrol · 1999 · Background
PubMed: PMID 10073603 · NCT07091175 (SMART-NS) · Nephrotic Syndrome
Interleukin-13: central mediator of allergic asthma.
Wills-Karp M, Luyimbazi J, Xu X, et al. · Science · 1999 · Background
PubMed: PMID 9856949 · NCT03884842 · Asthma
Validation of a standardized version of the Asthma Quality of Life Questionnaire.
Juniper EF, Buist AS, Cox FM, et al. · Chest · 1999 · Background
PubMed: PMID 10334138 · NCT03595488

1997 (1 paper)

Staging for rhinosinusitis.
Lund VJ, Kennedy DW · Otolaryngol Head Neck Surg · 1997 · Background
PubMed: PMID 9334786 · NCT03595488

1996 (1 paper)

Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements.
Pizzichini E, Pizzichini MM, Efthimiadis A, et al. · Am J Respir Crit Care Med · 1996 · Background
PubMed: PMID 8756799 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia

1995 (1 paper)

[The quality-of-life questionnaire with asthma patients: the Spanish version of the Asthma Quality of Life Questionnaire].
Sanjuàs C, Alonso J, Sanchís J, et al. · Arch Bronconeumol · 1995 · Background
PubMed: PMID 7788083 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia

1994 (1 paper)

Nasal cytology in patients with allergic rhinitis: effects of intranasal fluticasone propionate.
Meltzer EO, Orgel HA, Rogenes PR, et al. · J Allergy Clin Immunol · 1994 · Background
PubMed: PMID 7930304 · NCT05246267

1987 (1 paper)

Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.
Samuelsson B, Dahlén SE, Lindgren JA, et al. · Science · 1987 · Background
PubMed: PMID 2820055 · NCT03595488

1984 (3 papers)

Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin.
Stevenson DD, Pleskow WW, Simon RA, et al. · J Allergy Clin Immunol · 1984 · Background
PubMed: PMID 6368649 · NCT03595488
Skin tests.
Pepys J · Br J Hosp Med · 1984 · Background
PubMed: PMID 6478105 · NCT05787678 (DEBORA) · Pulmonary Eosinophilia
Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function.
Doty RL, Shaman P, Dann M, et al. · Physiol Behav · 1984 · Background
PubMed: PMID 6463130 · NCT03595488

1982 (1 paper)

[News about Crohn disease].
Bárány F · Lakartidningen · 1982 · Background
PubMed: PMID 7087618 · NCT07277322 · Colorectal Neoplasms

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Fri, 29 May 2026 17:22:18 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).